#  @FormalyTwilter 佐藤雄二 佐藤雄二 posts on X about $qure, $aspi, $tlph, $xbi the most. They currently have [---] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours. ### Engagements: [-----] [#](/creator/twitter::1885336611560579072/interactions)  - [--] Week [------] +1,558,800% - [--] Month [------] +1,955% - [--] Months [------] +818% ### Mentions: [--] [#](/creator/twitter::1885336611560579072/posts_active)  - [--] Months [--] -5.30% ### Followers: [---] [#](/creator/twitter::1885336611560579072/followers)  - [--] Week [---] +0.64% - [--] Month [---] +4% - [--] Months [---] +0.21% ### CreatorRank: [---------] [#](/creator/twitter::1885336611560579072/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) 53.15% [finance](/list/finance) 15.38% [cryptocurrencies](/list/cryptocurrencies) 8.39% [countries](/list/countries) 3.5% [financial services](/list/financial-services) #613 [technology brands](/list/technology-brands) 2.1% [social networks](/list/social-networks) 0.7% [exchanges](/list/exchanges) 0.7% **Social topic influence** [$qure](/topic/$qure) 7.69%, [$aspi](/topic/$aspi) #6, [$tlph](/topic/$tlph) 6.29%, [$xbi](/topic/$xbi) #52, [$vnda](/topic/$vnda) #7, [$nktr](/topic/$nktr) #79, [$eton](/topic/$eton) 4.9%, [eton](/topic/eton) 4.9%, [more info](/topic/more-info) #1869, [stocks](/topic/stocks) #3853 **Top accounts mentioned or mentioned by** [@mmatters22596](/creator/undefined) [@stocknear](/creator/undefined) [@aleabitoreddit](/creator/undefined) [@biotechautist](/creator/undefined) [@asamimes](/creator/undefined) [@brianskorney](/creator/undefined) [@leerinkpartners](/creator/undefined) [@clearstreetnews](/creator/undefined) [@biotech2k1](/creator/undefined) [@colemana64](/creator/undefined) [@teradasyacho](/creator/undefined) [@macrovet888](/creator/undefined) [@andreagtc](/creator/undefined) [@develiforever](/creator/undefined) [@regenxbio](/creator/undefined) [@regenxbios](/creator/undefined) [@cluelessbio](/creator/undefined) [@zethedeuce](/creator/undefined) **Top assets mentioned** [uniQure N.V. (QURE)](/topic/$qure) [ASP Isotopes Inc. (ASPI)](/topic/$aspi) [Huma Finance (HUMA)](/topic/$huma) [Kymera Therapeutics, Inc. (KYMR)](/topic/$kymr) [Alto Neuroscience, Inc. (ANRO)](/topic/$anro) [Tyra Biosciences, Inc. (TYRA)](/topic/$tyra) [Skyline Builders Group Holding Limited (SKBL)](/topic/$skbl) [Eli Lilly and Company (LLY)](/topic/$lly) [Sarepta Therapeutics, Inc. (SRPT)](/topic/$srpt) [Goldman Sachs (GS)](/topic/goldman-sachs) [Duolingo, Inc. (DUOL)](/topic/$duol) [Apogee Therapeutics, Inc. (APGE)](/topic/$apge) [Nuvation Bio Inc. (NUVB)](/topic/$nuvb) [Vertex Protocol (VRTX)](/topic/$vrtx) [Origin Protocol (OGN)](/topic/$ogn) [Agios Pharmaceuticals, Inc. (AGIO)](/topic/$agio) [Wave Life Sciences Ltd. Ordinary Shares (WVE)](/topic/$wve) [Biofrontera Inc. (BFRI)](/topic/$bfri) [Aardvark Therapeutics, Inc (AARD)](/topic/$aard) [Evommune, Inc. (EVMN)](/topic/$evmn) [Novo-Nordisk (NVO)](/topic/$nvo) [Cytokinetics Inc. (CYTK)](/topic/$cytk) [Enphase Energy Inc (ENPH)](/topic/$enph) [AbCellera Biologics Inc. (ABCL)](/topic/$abcl) [Madrigal Pharmaceuticals, Inc. Common Stock (MDGL)](/topic/$mdgl) [Amgen, Inc. (AMGN)](/topic/$amgn) [Merck & Co., Inc. (MRK)](/topic/$mrk) [GammaSwap (GS)](/topic/$gs) [Reddit, Inc. (RDDT)](/topic/$rddt) [Axsome Therapeutics, Inc (AXSM)](/topic/$axsm) [Turn Therapeutics, Inc. (TTRX)](/topic/$ttrx) [Hims & Hers Health, Inc. (HIMS)](/topic/$hims) [SoFi Technologies, Inc. Common Stock (SOFI)](/topic/sofi-technologies) ### Top Social Posts Top posts by engagements in the last [--] hours "$AGIO 400060% [----] [--] @stocknear There are [----] patients of thalassemia in USA . [--] percent are transfusion dependent. So at this price revenue should easily cross a billion dollars in USA alone in about [--] months.The market cap is [---] billion. Stock should easily double from here. @stocknear There are [----] patients of thalassemia in USA . [--] percent are transfusion dependent. So at this price revenue should easily cross a billion dollars in USA alone in about [--] months.The market cap is [---] billion. Stock should easily double from here" [X Link](https://x.com/FormalyTwilter/status/2019086609501610224) 2026-02-04T16:32Z [---] followers, [---] engagements "$AGIO AgiosPharmaceuticals FDA AQVESME AQVESME [-------] $AGIO Agios Pharmaceuticals shares are trading higher after the company announced the FDA approved AQVESME for the treatment of anemia in adults with alpha- or beta-thalassemia. An exect announced AQVESME will be introduce at approximately $425000 per patient per year. $AGIO Agios Pharmaceuticals shares are trading higher after the company announced the FDA approved AQVESME for the treatment of anemia in adults with alpha- or beta-thalassemia. An exect announced AQVESME will be introduce at approximately $425000 per patient per year" [X Link](https://x.com/FormalyTwilter/status/2019087618299105594) 2026-02-04T16:36Z [---] followers, [---] engagements "$MDGL [--] siRNA MASH [------] http://SuzhouRiboLifeScienceCo.Ltd $MDGL Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs with Suzhou Ribo Life Science Co. Lt US $60 million Upfront and cumulative payments across the programs could reach US $4.4 billion https://t.co/hYvsykdfgp http://SuzhouRiboLifeScienceCo.Ltd $MDGL Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs with Suzhou Ribo Life Science Co. Lt US $60 million Upfront and cumulative payments across the programs could" [X Link](https://x.com/FormalyTwilter/status/2021586061198037215) 2026-02-11T14:04Z [---] followers, [---] engagements "$SKBL $SKBL [--] Panamax 220DOE DOE LPO60-70% IP $ASPI #SKBL #Uranium Mandatory listen for all $SKBL investors: 2.2m lbs of uranium per year from [--] Panamax deployment. DOE tech. Supporting US domestic uranium supply. Highly confident about DOE LPO loan. Would cover 60-70% capex. Developing IP for suite of other metals. $ASPI Mandatory listen for all $SKBL investors: 2.2m lbs of uranium per year from [--] Panamax deployment. DOE tech. Supporting US domestic uranium supply. Highly confident about DOE LPO loan. Would cover 60-70% capex. Developing IP for suite of other metals. $ASPI" [X Link](https://x.com/FormalyTwilter/status/2018272383216627984) 2026-02-02T10:36Z [---] followers, [----] engagements "$QURE - FDA 150% vs 30% $QURE AMT-130 AA $CLPT $CLPT [--] $QURE potential stock moving catalyst- FDA meeting updates Potential upside 150% vs downside 30% Another stock that would surge big is $CLPT if $QURE gets the AA for AMT-130 $CLPT could more than double on positive news because it will be the confirmatory evidence for the $QURE potential stock moving catalyst- FDA meeting updates Potential upside 150% vs downside 30% Another stock that would surge big is $CLPT if $QURE gets the AA for AMT-130 $CLPT could more than double on positive news because it will be the confirmatory evidence for" [X Link](https://x.com/FormalyTwilter/status/2019090936052228237) 2026-02-04T16:49Z [---] followers, [---] engagements "$QURE $QURE $CLPT $QURE potential stock moving catalyst- FDA meeting updates Potential upside 150% vs downside 30% Another stock that would surge big is $CLPT if $QURE gets the AA for AMT-130 $CLPT could more than double on positive news because it will be the confirmatory evidence for the $QURE potential stock moving catalyst- FDA meeting updates Potential upside 150% vs downside 30% Another stock that would surge big is $CLPT if $QURE gets the AA for AMT-130 $CLPT could more than double on positive news because it will be the confirmatory evidence for the" [X Link](https://x.com/FormalyTwilter/status/2019091211034988608) 2026-02-04T16:50Z [---] followers, [----] engagements "$NKTR $QURE ( ) Catalist Actually I decided to start the fun early. Bot some $NKTR calls for maintenance data play and $QURE calls for FDA Type A meeting minutes play. Both fairly uncorrelated with broader market and charts look decent for bottom fishing with appropriate catalysts in place before my https://t.co/1tBX30s0Ae Actually I decided to start the fun early. Bot some $NKTR calls for maintenance data play and $QURE calls for FDA Type A meeting minutes play. Both fairly uncorrelated with broader market and charts look decent for bottom fishing with appropriate catalysts in place before" [X Link](https://x.com/FormalyTwilter/status/2019149142585704883) 2026-02-04T20:40Z [---] followers, [----] engagements "$LLY ( EliLilly )2026 Even with pricing headwinds Eli Lilly expects sales surge to continue in [----] https://t.co/AYFOXbf9NR Even with pricing headwinds Eli Lilly expects sales surge to continue in [----] https://t.co/AYFOXbf9NR" [X Link](https://x.com/FormalyTwilter/status/2019151935157465449) 2026-02-04T20:51Z [---] followers, [--] engagements "#FDA $AMGN #Amgen FDA Phase3 Amgen Tavneos - - FDA rehashing old Ph3 data and seeking to withdrawal of Amgen's Tavneos but company says it won't pull drug - very weird very unprecedented - https://t.co/trwypcvk6Z FDA rehashing old Ph3 data and seeking to withdrawal of Amgen's Tavneos but company says it won't pull drug - very weird very unprecedented - https://t.co/trwypcvk6Z" [X Link](https://x.com/FormalyTwilter/status/2019163874931667326) 2026-02-04T21:39Z [---] followers, [---] engagements "$ASPI PDRadiopharma PSMA *1 mCRPC 177Lu-PSMA-I&T Curium today announced that together with PeptiDream and PDRadiopharma the first patient has been dosed in the companies registrational clinical trial of 177Lu-PSMA-I&T in Japan for patients with PSMA (*1)-positive metastatic castration-resistant prostate cancer (mCRPC) $ASPI https://t.co/Anw7EPIg7l Curium today announced that together with PeptiDream and PDRadiopharma the first patient has been dosed in the companies registrational clinical trial of 177Lu-PSMA-I&T in Japan for patients with PSMA (*1)-positive metastatic" [X Link](https://x.com/FormalyTwilter/status/2019347140406112543) 2026-02-05T09:47Z [---] followers, [----] engagements "$SRPT $SRPT SRP-1005 $QURE $SRPT Announces Approval of Clinical Trial Application for SRP-1005 Its Investigational Treatment for Huntingtons Disease. $QURE https://t.co/vhXhb1HcMw $SRPT Announces Approval of Clinical Trial Application for SRP-1005 Its Investigational Treatment for Huntingtons Disease. $QURE https://t.co/vhXhb1HcMw" [X Link](https://x.com/FormalyTwilter/status/2019349998761308273) 2026-02-05T09:58Z [---] followers, [----] engagements "$QURE 10:30 $QURE [----] tomorrow. Thats when we get data $QURE [----] tomorrow. Thats when we get data" [X Link](https://x.com/FormalyTwilter/status/2019869412082479278) 2026-02-06T20:22Z [---] followers, [---] engagements "$QURE AMT-191 $QURE ( ) AMT-191 active drug dose-limiting toxicity (liver enzymes) but seems manageable. $QURE have to collect more data to substantiate the long-term medical benefits with an acceptable safety profile. Early solid data but no home run. Short term the FDA feedback on HD will be key. https://t.co/4A3R2vip6X AMT-191 active drug dose-limiting toxicity (liver enzymes) but seems manageable. $QURE have to collect more data to substantiate the long-term medical benefits with an acceptable safety profile. Early solid data but no home run. Short term the FDA feedback on HD will be" [X Link](https://x.com/FormalyTwilter/status/2019874484954787926) 2026-02-06T20:42Z [---] followers, [---] engagements "$QURE ( ) HD FDA AMT-191 active drug dose-limiting toxicity (liver enzymes) but seems manageable. $QURE have to collect more data to substantiate the long-term medical benefits with an acceptable safety profile. Early solid data but no home run. Short term the FDA feedback on HD will be key. https://t.co/4A3R2vip6X AMT-191 active drug dose-limiting toxicity (liver enzymes) but seems manageable. $QURE have to collect more data to substantiate the long-term medical benefits with an acceptable safety profile. Early solid data but no home run. Short term the FDA feedback on HD will be key." [X Link](https://x.com/FormalyTwilter/status/2019874644166340701) 2026-02-06T20:43Z [---] followers, [---] engagements "$WVE CantorFitzgerald Webinar $WVE WV-007 [-----] - - BMI100 $WVE: Listening to the Cantor Fitzgerald webinar with $WVE management. WV-007 data coming up is very impressive and they're excited. Confirmed it will be in Q1 [----]. -Great differentiated data. -Accelerating higher BMI fully enrolled study w/ [---] patients. $WVE: Listening to the Cantor Fitzgerald webinar with $WVE management. WV-007 data coming up is very impressive and they're excited. Confirmed it will be in Q1 [----]. -Great differentiated data. -Accelerating higher BMI fully enrolled study w/ [---] patients" [X Link](https://x.com/FormalyTwilter/status/2020030929071411265) 2026-02-07T07:04Z [---] followers, [---] engagements "$EIKN 200IPO $MRK 10% $XBI $IBB $EIKN Director acquires $2 million bucks at open market Fresh ipo. $MRK also took at 10% stake $XBI $IBB https://t.co/QlTNpPu5Ap $EIKN Director acquires $2 million bucks at open market Fresh ipo. $MRK also took at 10% stake $XBI $IBB https://t.co/QlTNpPu5Ap" [X Link](https://x.com/FormalyTwilter/status/2020035123950006533) 2026-02-07T07:21Z [---] followers, [---] engagements "#SPX #Stocks S&P500 CTA STOCK SELL-OFF NOT OVER GOLDMAN TRADERS SAY Goldman Sachs warns that US stocks could face more selling this week driven by trend-following funds known as CTAs which have already hit sell triggers in the S&P [---]. The bank estimates CTAs could dump up to $33 billion this week STOCK SELL-OFF NOT OVER GOLDMAN TRADERS SAY Goldman Sachs warns that US stocks could face more selling this week driven by trend-following funds known as CTAs which have already hit sell triggers in the S&P [---]. The bank estimates CTAs could dump up to $33 billion this week" [X Link](https://x.com/FormalyTwilter/status/2020597530829148649) 2026-02-08T20:36Z [---] followers, [---] engagements "#SPX #Stocks $GS CTA [---] - S&P500 [---] STOCK SELL-OFF NOT OVER GOLDMAN TRADERS SAY Goldman Sachs warns that US stocks could face more selling this week driven by trend-following funds known as CTAs which have already hit sell triggers in the S&P [---]. The bank estimates CTAs could dump up to $33 billion this week STOCK SELL-OFF NOT OVER GOLDMAN TRADERS SAY Goldman Sachs warns that US stocks could face more selling this week driven by trend-following funds known as CTAs which have already hit sell triggers in the S&P [---]. The bank estimates CTAs could dump up to $33 billion this week" [X Link](https://x.com/FormalyTwilter/status/2020598291533312296) 2026-02-08T20:39Z [---] followers, [---] engagements "@aleabitoreddit $RDDT" [X Link](https://x.com/FormalyTwilter/status/2020839611652853949) 2026-02-09T12:38Z [---] followers, [---] engagements "$AXSM [--] $AXSM ADA [---] PDUFA More unusual $AXSM options activity for February and March. Someone betting that a potential buyout happens before the April 30th PDUFA for ADA https://t.co/Lk3eAThcnk More unusual $AXSM options activity for February and March. Someone betting that a potential buyout happens before the April 30th PDUFA for ADA https://t.co/Lk3eAThcnk" [X Link](https://x.com/FormalyTwilter/status/2020843104878862840) 2026-02-09T12:51Z [---] followers, [---] engagements "$ETON 2026-02-09 : $14.76 PDUFA : 2026-02-25 ET-600 ( ( ) ) PoA: 85% 2026-02-25 $ETON 14.76$ PDUFA Date ET-600 PoA: 85% 2026-02-25 $ETON 14.76$ PDUFA Date ET-600 PoA: 85%" [X Link](https://x.com/FormalyTwilter/status/2020867244696215998) 2026-02-09T14:27Z [---] followers, [--] engagements "$ETON Catalist - 2026-02-25 - ET-600 - PoA85% https://biopharmawatch.com/company/ETON $ETON https://t.co/lwNT8GmOXU Catalyst Date - 2026-02-25 Drug - ET-600 (desmopressin oral solution) Treatment - central diabetes insipidus Poa : 85% https://biopharmawatch.com/company/ETON $ETON https://t.co/lwNT8GmOXU Catalyst Date - 2026-02-25 Drug - ET-600 (desmopressin oral solution) Treatment - central diabetes insipidus Poa : 85%" [X Link](https://x.com/FormalyTwilter/status/2020867860298436619) 2026-02-09T14:30Z [---] followers, [---] engagements "$ETON [---] ( 200DMA ) Eton pharma $eton new rare disease drug upcoming. Chart not far from breakout. We are below 200D so quarterly results better be good. https://t.co/zYWKjIkOE8 Eton pharma $eton new rare disease drug upcoming. Chart not far from breakout. We are below 200D so quarterly results better be good. https://t.co/zYWKjIkOE8" [X Link](https://x.com/FormalyTwilter/status/2020868956655878214) 2026-02-09T14:34Z [---] followers, [--] engagements "$ETON +3.75% EtonPharmaceuticals [---] FDA [----] https://notreload.xyz/eton-pharma-licenses-first-generic-ultra-rare-disease-drug/ $ETON +3.75% Eton Pharmaceuticals licenses U.S. rights to an ultra-rare disease treatment affecting under [---] patients expecting FDA approval and mid-2026 launch as first generic alternative. https://t.co/TRnDNA9ZxD https://t.co/h6ZQbBJrLH https://notreload.xyz/eton-pharma-licenses-first-generic-ultra-rare-disease-drug/ $ETON +3.75% Eton Pharmaceuticals licenses U.S. rights to an ultra-rare disease treatment affecting under [---] patients expecting FDA approval and" [X Link](https://x.com/FormalyTwilter/status/2020869546299547704) 2026-02-09T14:37Z [---] followers, [--] engagements "$ETON $ETON Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate https://t.co/9B4jYttsJn $ETON Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate https://t.co/9B4jYttsJn" [X Link](https://x.com/FormalyTwilter/status/2020870201902760196) 2026-02-09T14:39Z [---] followers, [--] engagements "$BFRI - Phase3 Ameluz 85%12% sNDA [-----] Catalist $BFRI - Phase [--] Ameluz results are in 85% complete response rate but stock's down 12% today. sNDA submission planned for Q3 [----] that's the next catalyst. $BFRI - Phase [--] Ameluz results are in 85% complete response rate but stock's down 12% today. sNDA submission planned for Q3 [----] that's the next catalyst" [X Link](https://x.com/FormalyTwilter/status/2020871919017644170) 2026-02-09T14:46Z [---] followers, [---] engagements "$TTRX - GX-03 Phase2 FDA Medline/MiMedx [----] 6.5% Phase3 [----] $TTRX - GX-03 Phase [--] hits FDA clears path 70M+ partnership with Medline/MiMedx is a nice boost. Still stock's down 6.5% today maybe due to high expectations. Phase [--] for eczema and onychomycosis is next slated for [----]. $TTRX - GX-03 Phase [--] hits FDA clears path 70M+ partnership with Medline/MiMedx is a nice boost. Still stock's down 6.5% today maybe due to high expectations. Phase [--] for eczema and onychomycosis is next slated for 2027" [X Link](https://x.com/FormalyTwilter/status/2020872464864079954) 2026-02-09T14:48Z [---] followers, [--] engagements "$HUMA Humacyte DOD [----] $Huma #Israel #Iran #Ukraine http://investors.humacyte.com/news-releases/news-release-details/humacyte-announces-new-us-department-defense-funding-procurement/ Humacyte announced DOD funding. Plus they have filed to be able to sell in Isreal should be approved in next 60-90 days or faster. $Huma #Israel #Iran #Ukraine https://t.co/1psvbFahOa https://t.co/hwzljqLJLe http://investors.humacyte.com/news-releases/news-release-details/humacyte-announces-new-us-department-defense-funding-procurement/ Humacyte announced DOD funding. Plus they have filed to be able to sell in" [X Link](https://x.com/FormalyTwilter/status/2020878119553683465) 2026-02-09T15:11Z [---] followers, [---] engagements "$HUMA $HUMA DOD 12% $HUMA surges 12% on DOD funding for its bioengineered vessels but the numbers demand caution: This is a speculative move on a procurement bill not revenue. Wait for real confirmation before trading the volatility. https://t.co/3j6bWJ9vyS $HUMA surges 12% on DOD funding for its bioengineered vessels but the numbers demand caution: This is a speculative move on a procurement bill not revenue. Wait for real confirmation before trading the volatility. https://t.co/3j6bWJ9vyS" [X Link](https://x.com/FormalyTwilter/status/2020878710250053840) 2026-02-09T15:13Z [---] followers, [---] engagements "$DUOL $HIMS 80% $DUOL seems to be the most hated stock in the entire market right now (excluding $HIMS). Yet the only argument I here is that it's down 80% from highs which for most investors means it must be trash. But take a look at the balance sheet. This company is dirt-cheap and won't https://t.co/PIiwzxkYA7 $DUOL seems to be the most hated stock in the entire market right now (excluding $HIMS). Yet the only argument I here is that it's down 80% from highs which for most investors means it must be trash. But take a look at the balance sheet. This company is dirt-cheap and won't" [X Link](https://x.com/FormalyTwilter/status/2020940110519468446) 2026-02-09T19:17Z [---] followers, [---] engagements "$DUOL $DUOL @MMatters22596 Cool infographics what's interesting in $DUOL's case is especially its growth in terms of paid subscribers: it's booming https://t.co/MiqW0f8Zd6 @MMatters22596 Cool infographics what's interesting in $DUOL's case is especially its growth in terms of paid subscribers: it's booming https://t.co/MiqW0f8Zd6" [X Link](https://x.com/FormalyTwilter/status/2020940729187696791) 2026-02-09T19:19Z [---] followers, [---] engagements "$DUOL @MMatters22596 The valuation is totally comical at this point. Anyone who still thinks this company is expensive has a poor feel for whats going on in the rest of the market and hasnt studied its financials enough @MMatters22596 The valuation is totally comical at this point. Anyone who still thinks this company is expensive has a poor feel for whats going on in the rest of the market and hasnt studied its financials enough" [X Link](https://x.com/FormalyTwilter/status/2020941021849452890) 2026-02-09T19:21Z [---] followers, [---] engagements "$SOFI GBULBorrow EVP SoFiTechnologies General Counsel joins the EVP of GBUL Borrow in buying the dip at SoFi Technologies $SOFI https://t.co/DV7TCjG9Fj General Counsel joins the EVP of GBUL Borrow in buying the dip at SoFi Technologies $SOFI https://t.co/DV7TCjG9Fj" [X Link](https://x.com/FormalyTwilter/status/2020944896572653820) 2026-02-09T19:36Z [---] followers, [---] engagements "$LTRX $QCOM $TER $LTRX $QCOM $TER $LTRX so much Reason with $QCOM and $TER Thermal for Drones and Robotcis https://t.co/AuZRaDuQNB $LTRX so much Reason with $QCOM and $TER Thermal for Drones and Robotcis https://t.co/AuZRaDuQNB" [X Link](https://x.com/FormalyTwilter/status/2020945671839510675) 2026-02-09T19:39Z [---] followers, [--] engagements "$CRVS $CRVS Ph1b/2 SQL 400mg QD [----] $CRVS Phase2 US/Global 400mg QD $CRVS CRVS's China partner is actively testing SQL 400mg QD in a Ph1b/2 study in China w/ topline data to come likely 2H26 which could provide early support for CRVS's planned 400mg QD cohort in Ph2 US/ global studies. $CRVS CRVS's China partner is actively testing SQL 400mg QD in a Ph1b/2 study in China w/ topline data to come likely 2H26 which could provide early support for CRVS's planned 400mg QD cohort in Ph2 US/ global studies" [X Link](https://x.com/FormalyTwilter/status/2020952056866144278) 2026-02-09T20:04Z [---] followers, [---] engagements "$VNDA - [---] PDUFA $vnda feb [--] PDUFA- likelyhood of advancing is high https://t.co/u116MGvCzG $vnda feb [--] PDUFA- likelyhood of advancing is high https://t.co/u116MGvCzG" [X Link](https://x.com/FormalyTwilter/status/2020968294833102913) 2026-02-09T21:09Z [---] followers, [---] engagements "$VNDA [--] [--] $XBI $LLY $VNDA should be trading 4x higher. 20x when the world discovers they have the numero uno late stage drug in the world that keeps obese people on their weight loss treatments.so sad this company has shitty management with little business acumen or marketing skills🤷♂ $XBI $LLy $VNDA should be trading 4x higher. 20x when the world discovers they have the numero uno late stage drug in the world that keeps obese people on their weight loss treatments.so sad this company has shitty management with little business acumen or marketing skills🤷♂ $XBI $LLy" [X Link](https://x.com/FormalyTwilter/status/2020969008368058771) 2026-02-09T21:12Z [---] followers, [---] engagements "$ETON $VNDA [--] PDUFA $ETON $VNDA $XBI Rough few days my focus will be on $ETON and $VNDA going into PDUFAs in Feb. $XBI Looking for good entries. Rough few days my focus will be on $ETON and $VNDA going into PDUFAs in Feb. $XBI Looking for good entries" [X Link](https://x.com/FormalyTwilter/status/2020969688520704198) 2026-02-09T21:14Z [---] followers, [---] engagements "$CRVS $APGE $NKTR $KYMR ( ) $NKTR + $KYMR /JAKi Key Differences Inclusion/Exclusion Criteria in Atopic Dermatitis Trials $CRVS Very high-bar patients w/ prior biologic/JAKi require failed therapy refractory $APGE Allows JAKi excludes prior IL-4/IL-13 $NKTR + $KYMR exlude prior biologics/JAKi or required nave patients https://t.co/3IF66KMKGJ Key Differences Inclusion/Exclusion Criteria in Atopic Dermatitis Trials $CRVS Very high-bar patients w/ prior biologic/JAKi require failed therapy refractory $APGE Allows JAKi excludes prior IL-4/IL-13 $NKTR + $KYMR exlude prior biologics/JAKi or" [X Link](https://x.com/FormalyTwilter/status/2021138917504974895) 2026-02-10T08:27Z [---] followers, [---] engagements "$AARD - Phase3 HERO [--] ToplineData [--] $BIOA $IBIO $AARD - Expands Phase [--] HERO trial to kids 7+. Toline data still on track for Q3 competitive landscape with $BIOA and $IBIO getting interesting. $AARD - Expands Phase [--] HERO trial to kids 7+. Toline data still on track for Q3 competitive landscape with $BIOA and $IBIO getting interesting" [X Link](https://x.com/FormalyTwilter/status/2021220085587734642) 2026-02-10T13:49Z [---] followers, [---] engagements "$AARD ARD-101 Phase3 FDA IRB $AARD Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101 Expanding Eligibility in Phase [--] Study of Prader-Willi Syndrome https://t.co/ornKXpfW0m $AARD Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101 Expanding Eligibility in Phase [--] Study of Prader-Willi Syndrome https://t.co/ornKXpfW0m" [X Link](https://x.com/FormalyTwilter/status/2021220935684997280) 2026-02-10T13:53Z [---] followers, [--] engagements "$EVMN - Evommune EVO301 Phase2a $EVMN - Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis. $EVMN - Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis" [X Link](https://x.com/FormalyTwilter/status/2021221749845529082) 2026-02-10T13:56Z [---] followers, [--] engagements "$VNDA VandaPharmaceuticals HETLIOZ FDA https://pryzm.ozmosi.com/product/2117 $VNDA Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ Supplemental New Drug Application for Jet Lag Disorder More Info: https://t.co/zM6GMxghuK https://t.co/9CDllQv1ob https://pryzm.ozmosi.com/product/2117 $VNDA Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ Supplemental New Drug Application for Jet Lag Disorder More Info: https://t.co/zM6GMxghuK https://t.co/9CDllQv1ob" [X Link](https://x.com/FormalyTwilter/status/2021580953584345434) 2026-02-11T13:43Z [---] followers, [---] engagements "$ASPI [---] Goldman Sachs buys [-------] shares more of $ASPI https://t.co/sbrepJtISQ Goldman Sachs buys [-------] shares more of $ASPI https://t.co/sbrepJtISQ" [X Link](https://x.com/FormalyTwilter/status/2021584400060735824) 2026-02-11T13:57Z [---] followers, [---] engagements "$ASPI BNPParibasAssetManagementUK files 13G disclosing ownership of close to 1mm shares of $ASPI $ASPI BNP Paribas Asset Management UK files 13G disclosing ownership of close to 1mm shares of ASPI $ASPI BNP Paribas Asset Management UK files 13G disclosing ownership of close to 1mm shares of ASPI" [X Link](https://x.com/FormalyTwilter/status/2021585124748398861) 2026-02-11T14:00Z [---] followers, [---] engagements "$ASPI BNPUK 13G$ASPI [---] $ASPI BNP Paribas Asset Management UK files 13G disclosing ownership of close to 1mm shares of ASPI $ASPI BNP Paribas Asset Management UK files 13G disclosing ownership of close to 1mm shares of ASPI" [X Link](https://x.com/FormalyTwilter/status/2021585376104649039) 2026-02-11T14:01Z [---] followers, [---] engagements "$ASPI $ASPI TaronisFuels IR $ASPI I find it interesting that Michael Khorassani is also promoting ASPI for those who dont know he was doing IR for Taronis Fuels a proven industrial tech fraud. https://t.co/bhFufG56od https://t.co/nrF42YH4Jo $ASPI I find it interesting that Michael Khorassani is also promoting ASPI for those who dont know he was doing IR for Taronis Fuels a proven industrial tech fraud. https://t.co/bhFufG56od https://t.co/nrF42YH4Jo" [X Link](https://x.com/FormalyTwilter/status/2021622313326882816) 2026-02-11T16:28Z [---] followers, [---] engagements "$VNDA 📉 ⚡ 7/10 : $VNDA4 💡 VNDA10.1% 👉 #Traders #Hours #Stocks https://fibalgo.com/terminal 📉 BEARISH ⚡ 7/10 After-hours healthcare small-caps volatile; VNDA drops on Q4 earnings $VNDA 💡 The news highlights significant after-hours price movements in low-market-cap healthcare stocks with VNDA declining [----] 👉 https://t.co/M6U3eWkjtJ #Traders #Hours #Stocks https://fibalgo.com/terminal 📉 BEARISH ⚡ 7/10 After-hours healthcare small-caps volatile; VNDA drops on Q4 earnings $VNDA 💡 The news highlights significant after-hours price movements in low-market-cap healthcare stocks with VNDA" [X Link](https://x.com/FormalyTwilter/status/2021704202121330950) 2026-02-11T21:53Z [---] followers, [---] engagements "# # # Consolidated financial results for the fiscal year ending December Otsuka Holdings' net profit increases [---] times. Net profit and sales both reach record highs with pharmaceuticals performing well. #OtsukaPharmaceutical #Otsuka $ESPR # # # HD28 [--] https://t.co/1piRenXK3r # # # HD28 [--] https://t.co/1piRenXK3r" [X Link](https://x.com/FormalyTwilter/status/1962212387702087780) 2025-08-31T17:54Z [---] followers, [---] engagements "$ANRO #ALTO-101 ALTO-101 PDE4 PDE4 cAMP ( )" [X Link](https://x.com/FormalyTwilter/status/2013351829799870742) 2026-01-19T20:44Z [---] followers, [---] engagements "$ASPI $QLE $SKBL ( ) TerraPower $ASPI $ASPI $QLE $SKBL Graphic we recently put together to help better understand how these companies connect. $QLE will be interesting to see how IPO and HALEU deadlines pan out. TerraPower made it clear $ASPI was the only company who could meet their timeline and demand. https://t.co/suZSl9Ok1p $ASPI $QLE $SKBL Graphic we recently put together to help better understand how these companies connect. $QLE will be interesting to see how IPO and HALEU deadlines pan out. TerraPower made it clear $ASPI was the only company who could meet their timeline and demand." [X Link](https://x.com/FormalyTwilter/status/2017234894271951268) 2026-01-30T13:54Z [---] followers, [---] engagements "$TYRA #OPPENHEIMER MatthewBiegler $TYRA AnaChart [------] 3#Pricetarget $36$50 $4.98 (16.05%) $18.98 (61.19%) Outperform #OPPENHEIMER analyst Matthew Biegler who covers $TYRA has the current 3rd biggest #pricetarget movement on AnaChart (03-Feb-2026 (10AM)) by upgrading from $36 to $50 with an increase in potential upside change from $4.98(16.05%) to $18.98(61.19%) with a rating of Outperform https://t.co/W9u958dQnd #OPPENHEIMER analyst Matthew Biegler who covers $TYRA has the current 3rd biggest #pricetarget movement on AnaChart (03-Feb-2026 (10AM)) by upgrading from $36 to $50 with an" [X Link](https://x.com/FormalyTwilter/status/2019327751719911736) 2026-02-05T08:30Z [---] followers, [--] engagements "$TYRA - Phase2 🚀 ➤ -0.88% +11.33% - ➤ RVOL [----] - ➤ [-----] / 17.65% - $TYRA dosed first child in Phase 2; shares surge 🚀 ➤ +11.33% intraday after a -0.88% gap momentum confirmed ➤ RVOL [----] above-average trading interest ➤ Short Ratio [-----] / Short Float 17.65% meaningful short-squeeze risk https://t.co/RfRZyPogmU $TYRA dosed first child in Phase 2; shares surge 🚀 ➤ +11.33% intraday after a -0.88% gap momentum confirmed ➤ RVOL [----] above-average trading interest ➤ Short Ratio [-----] / Short Float 17.65% meaningful short-squeeze risk https://t.co/RfRZyPogmU" [X Link](https://x.com/FormalyTwilter/status/2019328462776049866) 2026-02-05T08:33Z [---] followers, [--] engagements "$TYRA BiotechAnalyst ChrisRaymond $TYRA Layering UTUC Into Our Dabogratinib Model$TYRA Dabogratinib Biotech analyst Chris Raymond published on $TYRA "Layering UTUC Into Our Dabogratinib Model" calling out that although this is smaller opportunity TYRA can accelerate development here with the potential for this to be the first approved indication for dabogratinib. Biotech analyst Chris Raymond published on $TYRA "Layering UTUC Into Our Dabogratinib Model" calling out that although this is smaller opportunity TYRA can accelerate development here with the potential for this to be the first" [X Link](https://x.com/FormalyTwilter/status/2019331900352131334) 2026-02-05T08:46Z [---] followers, [--] engagements "$ALXO Director [---] Catalist ( ) Phase2 [--] - + - ( ASPEN-09-Breast ) HER2 Phase1 [----] - ALX2004 - $XBI $IBB $ALXO Director acquires $5 million dollars at open market Catalyst: Phase [--] interim data Q3 -Evorpacept + trastuzumab - (ASPEN-09-Breast) HER2-positive metastatic breast cancer Phase [--] 1H [----] ALX2004 Solid Tumors $XBI $IBB https://t.co/m1ID3Ym3kJ $ALXO Director acquires $5 million dollars at open market Catalyst: Phase [--] interim data Q3 -Evorpacept + trastuzumab - (ASPEN-09-Breast) HER2-positive metastatic breast cancer Phase [--] 1H [----] ALX2004 Solid Tumors $XBI $IBB" [X Link](https://x.com/FormalyTwilter/status/2019349321813283029) 2026-02-05T09:56Z [---] followers, [---] engagements "$TYRA - Jefferies TyraBiosciences ( PT ) $32$43 : $TYL -Needham reiterates Tyler Technologies $750 target Buy -DA Davidson maintains $510 target Neutral - $TYRA -Jefferies raises Tyra Biosciences target to $43 from $32 Buy - $UAL -Citi adds United Airlines to upside [--] day catalyst watch Raises target to $155 from $153 Buy - $TYL -Needham reiterates Tyler Technologies $750 target Buy -DA Davidson maintains $510 target Neutral - $TYRA -Jefferies raises Tyra Biosciences target to $43 from $32 Buy - $UAL -Citi adds United Airlines to upside [--] day catalyst watch Raises target to $155 from" [X Link](https://x.com/FormalyTwilter/status/2020524300034343239) 2026-02-08T15:45Z [---] followers, [--] engagements "$BFRI [---] Q4 [----] $BFRI looking juicy here. Trading just below 1x sales with multiple approvals next [--] months and breakeven this year. Beat q4 estimates and I suspect they hit closer to 50mm this year then its off to the races $BFRI looking juicy here. Trading just below 1x sales with multiple approvals next [--] months and breakeven this year. Beat q4 estimates and I suspect they hit closer to 50mm this year then its off to the races" [X Link](https://x.com/FormalyTwilter/status/2020835306057126087) 2026-02-09T12:20Z [---] followers, [---] engagements "$ETON $KYTX $ETON 2/25 PDUFA $KYTX Phase2 BLA2026 Phase2 Catalist @BiotechAutist @asamimes @BrianSkorney @LeerinkPartners @ClearStreetNews Well $ETON has PDUFA on2/25. $KYTX has a nr of potential catalysts with readings (Ph2 stiff person syndrome BLA filling interim Ph2 myasthenia gravis extended in 2026) @BiotechAutist @asamimes @BrianSkorney @LeerinkPartners @ClearStreetNews Well $ETON has PDUFA on2/25. $KYTX has a nr of potential catalysts with readings (Ph2 stiff person syndrome BLA filling interim Ph2 myasthenia gravis extended in 2026)" [X Link](https://x.com/FormalyTwilter/status/2020870937193665009) 2026-02-09T14:42Z [---] followers, [---] engagements "$XBI / $ARDX $DAWN $SLNO $TMDX $HROW #ARDX #DAWN #SLNO #TMDX #HROW #XBI $XBI few small cap biotech companies that still seems undervalued with approved drug (s) on the market. De-risked as earnings and drug launches have done better than before $ARDX $DAWN $SLNO $TMDX $HROW $XBI few small cap biotech companies that still seems undervalued with approved drug (s) on the market. De-risked as earnings and drug launches have done better than before $ARDX $DAWN $SLNO $TMDX $HROW" [X Link](https://x.com/FormalyTwilter/status/2020894097624678608) 2026-02-09T16:14Z [---] followers, [--] engagements "$NUVB NuvationBio IDH1 Safusidenib Phase3 SIGMA G203 https://pryzm.ozmosi.com/product/22745 $NUVB Nuvation Bio Announces Pivotal Global Phase [--] SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma More Info: https://t.co/ybrR3GaTOQ https://t.co/4ABtiXo1GM https://pryzm.ozmosi.com/product/22745 $NUVB Nuvation Bio Announces Pivotal Global Phase [--] SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma More Info: https://t.co/ybrR3GaTOQ https://t.co/4ABtiXo1GM" [X Link](https://x.com/FormalyTwilter/status/2020938306322829398) 2026-02-09T19:10Z [---] followers, [---] engagements "$NUVB IDH1 ( Safusidenib ) Phase3 G203 $NUVB Announces Pivotal Global Phase [--] SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma https://t.co/Xk3LO2x2ix $NUVB Announces Pivotal Global Phase [--] SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma https://t.co/Xk3LO2x2ix" [X Link](https://x.com/FormalyTwilter/status/2020943783182074328) 2026-02-09T19:31Z [---] followers, [---] engagements "$VRTX $VNDA Vertex [----] Jounravx [---] $VRTX $VNDA Vertex plans to triple Jounravx patients to [---] million in [----] while expanding into pain and renal disease franchises $VRTX $VNDA Vertex plans to triple Jounravx patients to [---] million in [----] while expanding into pain and renal disease franchises" [X Link](https://x.com/FormalyTwilter/status/2021583261336502279) 2026-02-11T13:53Z [---] followers, [---] engagements "$VRTX JOURNAVXsuzetrigine [--] NaV1.8" [X Link](https://x.com/FormalyTwilter/status/2021583656356061244) 2026-02-11T13:54Z [---] followers, [--] engagements "$GELS Gelteq HealthyExtracts $GELS Gelteq and Healthy Extracts to Expand Gel-Based Nutrition Technologies with New Strategic Manufacturing & Commercial Partnership https://t.co/a6wM5mOovm $GELS Gelteq and Healthy Extracts to Expand Gel-Based Nutrition Technologies with New Strategic Manufacturing & Commercial Partnership https://t.co/a6wM5mOovm" [X Link](https://x.com/FormalyTwilter/status/2021695973102067824) 2026-02-11T21:20Z [---] followers, [--] engagements "$VNDA Vanda VQW-765 YE26 Phase3 Phobia Social $VNDA Vanda announced they will present P3 Phobia Social results in YE26 for VQW-765 More Info: https://t.co/YkHjDciIlR https://t.co/Y3A6l8KLcf $VNDA Vanda announced they will present P3 Phobia Social results in YE26 for VQW-765 More Info: https://t.co/YkHjDciIlR https://t.co/Y3A6l8KLcf" [X Link](https://x.com/FormalyTwilter/status/2022045512900419966) 2026-02-12T20:29Z [---] followers, [--] engagements "$VNDA Vanda Milsaperidone Phase3 YE26 $VNDA Vanda announced they will present P3 Depressive Disorder Major results in YE26 for Milsaperidone More Info: https://t.co/5cBb1LRf5w https://t.co/nH2ssEtTAW $VNDA Vanda announced they will present P3 Depressive Disorder Major results in YE26 for Milsaperidone More Info: https://t.co/5cBb1LRf5w https://t.co/nH2ssEtTAW" [X Link](https://x.com/FormalyTwilter/status/2022046139214950417) 2026-02-12T20:32Z [---] followers, [---] engagements "$NKTR Rezpegaldesleukin Rezpeg NektarTherapeutics T RegulatoryTcell : Treg IL-2 ( )" [X Link](https://x.com/FormalyTwilter/status/2022064724628893979) 2026-02-12T21:46Z [---] followers, [---] engagements "$NKTR ( ) IL-13 Rezpeg First-in-class Treg" [X Link](https://x.com/FormalyTwilter/status/2022064999393534282) 2026-02-12T21:47Z [---] followers, [---] engagements "$OGN Organon 2025Q4 📊 ❌ EPS: $0.63 : 30.00% (from $0.90) ❌ : $1.507B : 5.34% (from $1.592B) 📊 Organon $OGN Q4 [----] Earnings ❌ Earnings Miss Adj. EPS: $0.63 YoY: 30.00% (from $0.90) ❌ Revenue Miss Sales: $1.507B YoY: 5.34% (from $1.592B) 📊 Organon $OGN Q4 [----] Earnings ❌ Earnings Miss Adj. EPS: $0.63 YoY: 30.00% (from $0.90) ❌ Revenue Miss Sales: $1.507B YoY: 5.34% (from $1.592B)" [X Link](https://x.com/FormalyTwilter/status/2022166180346372106) 2026-02-13T04:29Z [---] followers, [--] engagements "$OGN [------] Nexplanon 7% $OGN - [----] revenue hits $6.2B Launched new biosimilars and chopped debt. Nexplanon patents expire soon though and that's a big chunk of revenue. Down 7% today. $OGN - [----] revenue hits $6.2B Launched new biosimilars and chopped debt. Nexplanon patents expire soon though and that's a big chunk of revenue. Down 7% today" [X Link](https://x.com/FormalyTwilter/status/2022167271632990264) 2026-02-13T04:33Z [---] followers, [--] engagements "$ASPI $ASPI [---] BlackRock buys [----] millions shares more of $ASPI https://t.co/5Tkywq81yN BlackRock buys [----] millions shares more of $ASPI https://t.co/5Tkywq81yN" [X Link](https://x.com/FormalyTwilter/status/2022301289670180878) 2026-02-13T13:26Z [---] followers, [----] engagements "$OCUL $OCUL AXPAXLI AMD SOL-1 Phase3 [-----] [--] $OCUL topline results of the SOL-1 Phase [--] superiority clinical trial of AXPAXLI for the treatment of wet AMD are expected to be presented at the 49th Macula Society Annual Meeting taking place between Feb 25th 28th $OCUL topline results of the SOL-1 Phase [--] superiority clinical trial of AXPAXLI for the treatment of wet AMD are expected to be presented at the 49th Macula Society Annual Meeting taking place between Feb 25th 28th" [X Link](https://x.com/FormalyTwilter/status/2022316832246710440) 2026-02-13T14:28Z [---] followers, [---] engagements "#Iran #Uranium #HEU 400HEU Iran official says Tehran considering handing over [---] kg of highly enriched uranium (HEU) accepting zero enrichment under a consortium arrangement as a solution in a deal that should also include lifting economic sanctions https://t.co/ESN8OQiS9s Iran official says Tehran considering handing over [---] kg of highly enriched uranium (HEU) accepting zero enrichment under a consortium arrangement as a solution in a deal that should also include lifting economic sanctions https://t.co/ESN8OQiS9s" [X Link](https://x.com/FormalyTwilter/status/2022420021931315579) 2026-02-13T21:18Z [---] followers, [---] engagements "$KYMR $CRVS $APGE Phase2b AD ( ) Different Ph2b AD trial designs orals may take less time than injectables and close gap w/ injectable programs further ahead oral $KYMR KT-621 [--] wks [--] wk open label extension $CRVS #soquelitinib [--] wks 30-day follow-up inj $APGE $NKTR 16wk data [--] wk maintenance https://t.co/EocGY0UPie Different Ph2b AD trial designs orals may take less time than injectables and close gap w/ injectable programs further ahead oral $KYMR KT-621 [--] wks [--] wk open label extension $CRVS #soquelitinib [--] wks 30-day follow-up inj $APGE $NKTR 16wk data [--] wk maintenance" [X Link](https://x.com/FormalyTwilter/status/2022422074376216772) 2026-02-13T21:26Z [---] followers, [---] engagements "$KYMR $CRVS $APGE $NKTR ( ) - $KYMR KT-6211652 $CRVS #1230 - $APGE $NKTR [----] Different Ph2b AD trial designs orals may take less time than injectables and close gap w/ injectable programs further ahead oral $KYMR KT-621 [--] wks [--] wk open label extension $CRVS #soquelitinib [--] wks 30-day follow-up inj $APGE $NKTR 16wk data [--] wk maintenance https://t.co/EocGY0UPie Different Ph2b AD trial designs orals may take less time than injectables and close gap w/ injectable programs further ahead oral $KYMR KT-621 [--] wks [--] wk open label extension $CRVS #soquelitinib [--] wks 30-day follow-up inj $APGE" [X Link](https://x.com/FormalyTwilter/status/2022422377184006630) 2026-02-13T21:27Z [---] followers, [---] engagements "$CRVS ITK #Soquelitinib AD 🔹 🔹 EASI-75 🔹 $NKTR $KYMR $EVMN $CRVS Mizuho discusses oral ITK inhibitor #soquelitinib recent AD data: 🔹 "Data were VERY excellent in terms of efficacy and also in terms of safety" 🔹 "Best-in-Class EASI-75 almost Best-in-Disease type of efficacy" 🔹 "intriguing signals that you can get durative efficacy" https://t.co/6WkozViVTB $CRVS Mizuho discusses oral ITK inhibitor #soquelitinib recent AD data: 🔹 "Data were VERY excellent in terms of efficacy and also in terms of safety" 🔹 "Best-in-Class EASI-75 almost Best-in-Disease type of efficacy" 🔹 "intriguing" [X Link](https://x.com/FormalyTwilter/status/2022424256702030042) 2026-02-13T21:34Z [---] followers, [---] engagements "@Biotech2k1 No. I'm "JAPANESE "" [X Link](https://x.com/FormalyTwilter/status/1951387046767108526) 2025-08-01T20:58Z [---] followers, [----] engagements "$QNCX JMPQuince Therapeutics $QNCX coverageOutperform [--] [----] $XBI $SRPT $VRTX Citizens JMP initiated coverage of Quince Therapeutics $QNCX with an Outperform rating and $9 PT Current price: $1.69 $XBI $SRPT $VRTX Citizens JMP initiated coverage of Quince Therapeutics $QNCX with an Outperform rating and $9 PT Current price: $1.69 $XBI $SRPT $VRTX" [X Link](https://x.com/FormalyTwilter/status/1952728259038191844) 2025-08-05T13:47Z [---] followers, [---] engagements "$QNCX The Lancet Neurology $QNCX Phase3 Phase3 6-9 $XBI $ABVX $SRPT This is what I mean see $QNCX prior Ph3 data published by The Lancet Neurology Look at current Ph3 trial primary population (6-9y) numbers off the charts $XBI $ABVX $SRPT https://t.co/eU1iTpNrOz This is what I mean see $QNCX prior Ph3 data published by The Lancet Neurology Look at current Ph3 trial primary population (6-9y) numbers off the charts $XBI $ABVX $SRPT https://t.co/eU1iTpNrOz" [X Link](https://x.com/FormalyTwilter/status/1952729920079306893) 2025-08-05T13:54Z [---] followers, [---] engagements "$ARVN Logos $SLRN $KROS =5 $ARVN Logos joining the special distribution-gang. One of those ugly registers with a large block of passive capital which will vote for every dumb thing management puts out (see SLRN KROS). Only am short Puts (Strike=5). Might put something more aggressive on. https://t.co/64Qf5o8IHe $ARVN Logos joining the special distribution-gang. One of those ugly registers with a large block of passive capital which will vote for every dumb thing management puts out (see SLRN KROS). Only am short Puts (Strike=5). Might put something more aggressive on. https://t.co/64Qf5o8IHe" [X Link](https://x.com/FormalyTwilter/status/1953476991677550661) 2025-08-07T15:23Z [---] followers, [---] engagements "$NRXP NRx Pharmaceuticals Inc.NASDAQ: $NRXP NRX-100 FDA - #PharmaNews #Mentalillness #Mentalhealth #mentalhealthmatters #Ketamin https://ir.nrxpharma.com/news-releases/news-release-details/nrx-pharmaceuticals-inc-nasdaqnrxp-granted-fda-fast-track NRx Pharmaceuticals Inc. (NASDAQ: $NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression including Bipolar Depression Read More - https://t.co/ifD2YPCCCJ #PharmaNews #mentalillness #mentalhealth #mentalhealthmatters #ketamine" [X Link](https://x.com/FormalyTwilter/status/1955020564701270295) 2025-08-11T21:36Z [---] followers, [---] engagements "$HUMA Humacyte Inc. Symvess" [X Link](https://x.com/anyuser/status/1956015795525575013) 2025-08-14T15:31Z [---] followers, [---] engagements "$QURE AAV AMT-130 $PTCT $WVE $NBIX $IONS - $RHHBY $TEVA $KRRO $HLUBF $HLBBF Mizuho $QURE to OP-$30 from N-$20. $PTCT $WVE $NBIX $IONS - $RHHBY $TEVA $KRRO $HLUBF $HLBBF Mizuho: We upgrade $QURE from Neutral to Outperform and increase our PT from $20 to $30 as (1) we believe AMT-130 could be a dominant player in the evolving Huntington's disease (HD) Mizuho $QURE to OP-$30 from N-$20. $PTCT $WVE $NBIX $IONS - $RHHBY $TEVA $KRRO $HLUBF $HLBBF Mizuho: We upgrade $QURE from Neutral to Outperform and increase our PT from $20 to $30 as (1) we believe AMT-130 could be a dominant player in the" [X Link](https://x.com/FormalyTwilter/status/1956033217150251038) 2025-08-14T16:40Z [---] followers, [---] engagements "$LXRX $NVO [--] LX9851 [---] 🚀 🚨 $LXRX Lexicon Pharmaceuticals can be a game changer in the weight-loss drug marketafter revealing a $1 billion deal with the leading company $NVO Novo Nordisk on drug LX9851. Besides the high 5% borrow fee and 15% short volume are ideal for a potential short squeeze🚀 https://t.co/PpJvDLskpN 🚨 $LXRX Lexicon Pharmaceuticals can be a game changer in the weight-loss drug marketafter revealing a $1 billion deal with the leading company $NVO Novo Nordisk on drug LX9851. Besides the high 5% borrow fee and 15% short volume are ideal for a potential short squeeze🚀" [X Link](https://x.com/anyuser/status/1957485382620311558) 2025-08-18T16:50Z [---] followers, [---] engagements "$LXRX Genome5000 [---] Finally getting some recognition $LXRX . focused on developing innovative medicines through its Genome5000 program which has identified over [---] protein targets with therapeutic potential https://t.co/3zYFUw4okb Finally getting some recognition $LXRX . focused on developing innovative medicines through its Genome5000 program which has identified over [---] protein targets with therapeutic potential https://t.co/3zYFUw4okb" [X Link](https://x.com/anyuser/status/1957485735071871228) 2025-08-18T16:52Z [---] followers, [---] engagements "$TNXP FDATONMYA FDA Approves TONMYA (cyclobenzaprine sublingual tablet) for Fibromyalgia https://t.co/OmaKGUfCCZ FDA Approves TONMYA (cyclobenzaprine sublingual tablet) for Fibromyalgia https://t.co/OmaKGUfCCZ" [X Link](https://x.com/FormalyTwilter/status/1957810144638632014) 2025-08-19T14:21Z [---] followers, [---] engagements "$UNCY 815FDA [--] @colemana64 Yes that may be the point of these bogus lawsuits to bring down the price. In most cases the short is behind. But honestly today's price decline may be directly attributable to 15Aug financing. It will quickly come back up in anticipation of FDA Type [--] Meeting feedback any day @colemana64 Yes that may be the point of these bogus lawsuits to bring down the price. In most cases the short is behind. But honestly today's price decline may be directly attributable to 15Aug financing. It will quickly come back up in anticipation of FDA Type [--] Meeting feedback any day" [X Link](https://x.com/anyuser/status/1958167460668174422) 2025-08-20T14:01Z [---] followers, [---] engagements "$ARDX $ARDX 2025162024119% 📍637 📍202589 📍2025 $ARDX Kyowa Kirin who license the tenapanor drug from $ARDX announced a 119% increase in sales for the Jan-Jun [----] period compared to [----]. 📍In first [--] months they did [---] Bill in sales. 📍Their target for FY25 is [---] Bill. 📍That means they're expecting a strong 2h'25. https://t.co/mtplRwxCyU $ARDX Kyowa Kirin who license the tenapanor drug from $ARDX announced a 119% increase in sales for the Jan-Jun [----] period compared to [----]. 📍In first [--] months they did [---] Bill in sales. 📍Their target for FY25 is [---] Bill. 📍That means they're" [X Link](https://x.com/FormalyTwilter/status/1958213691507343727) 2025-08-20T17:05Z [---] followers, [---] engagements "Upcoming Catalysts for Next Week Aug [--] 2025: $OSTX $OTLK Aug [--] 2025: $SNY $NVS $COYA Aug [--] 2025: $CYTK $RPRX $RHHBY $ALNY" [X Link](https://x.com/anyuser/status/1959000625364304099) 2025-08-22T21:12Z [---] followers, [---] engagements "$NTLA $CRSP $BEAM $PRME [--] Turns out I slept on Paul Grahams bullish gene-editing prophecy from last Feb. Here it is in case you missed it too I think he knows a thing or two. $NTLA $CRSP $BEAM $PRME Turns out I slept on Paul Grahams bullish gene-editing prophecy from last Feb. Here it is in case you missed it too I think he knows a thing or two. $NTLA $CRSP $BEAM $PRME" [X Link](https://x.com/anyuser/status/1959139585788891388) 2025-08-23T06:24Z [---] followers, [---] engagements "@teradasyacho 10" [X Link](https://x.com/FormalyTwilter/status/1959608897087643733) 2025-08-24T13:29Z [---] followers, [----] engagements "$ENPH Enphase [----] TPO IQ8HC $ENPH SECURES $50M SOLAR FINANCING DEAL UP 11% IN [--] WEEK Bullish vibes are building for solar if tax credits stick and financing costs ease. A drop in rates on residential loans could fuel another leg higher for the sector. Enphase signed a safe harbor agreement with a solar https://t.co/JPZWzx2nXE $ENPH SECURES $50M SOLAR FINANCING DEAL UP 11% IN [--] WEEK Bullish vibes are building for solar if tax credits stick and financing costs ease. A drop in rates on residential loans could fuel another leg higher for the sector. Enphase signed a safe harbor agreement with a" [X Link](https://x.com/FormalyTwilter/status/1959622329291645063) 2025-08-24T14:22Z [---] followers, [--] engagements "Yamaha Motor Co. Ltd. [----] World's No. [--] in Motorcycles World's No. [--] in Outboard Motors and Personal Watercraft PER: 23x PBR: 0.9x Forecast Dividend Yield: 4.6% Forecast Dividend Payout: 108% Financial Results☁ Forecast EPS: [--] Dividend: [--] [----] [--] [--] PER23 PBR0.9 4.6% 108% ☁ EPS4650 https://t.co/zCaN5J3Zzc [----] [--] [--] PER23 PBR0.9 4.6% 108% ☁ EPS4650 https://t.co/zCaN5J3Zzc" [X Link](https://x.com/FormalyTwilter/status/1959654461254840623) 2025-08-24T16:30Z [---] followers, [---] engagements "$CAPR $REPL $CAPR $REPL CRL AdComms Prasad FDA FDA Vinay CBER RCT 2/ In both $CAPR and $REPL CRLs (both w/o AdComms) Prasad (and other senior FDA leaders) overruled FDA reviewers. This was a behavior Vinay criticized previous CBER head for. These decisions support his critics' labelling of him only accepting RCTs. https://t.co/plY5oSPOvs 2/ In both $CAPR and $REPL CRLs (both w/o AdComms) Prasad (and other senior FDA leaders) overruled FDA reviewers. This was a behavior Vinay criticized previous CBER head for. These decisions support his critics' labelling of him only accepting RCTs." [X Link](https://x.com/FormalyTwilter/status/1960008682621792331) 2025-08-25T15:57Z [---] followers, [---] engagements "$SNYR : $9.1M (+33% YoY) 77.8% (72.1%) : $1.2M (+58% YoY) $HCWB $OSRH $OPAD $CAPS $STSS $AEHR $CGTX $SUPX $HIT $TWOH $DTREF $AIBT 🚀 $SNYR: Major Distribution Breakthrough & Profit Surge Revenue: $9.1M (+33% YoY). Gross Margin Hit 77.8% (up from 72.1% YoY) industry-leading profitability. Net Income: $1.2M (+58% YoY). $HCWB $OSRH $OPAD $CAPS $STSS $AEHR $CGTX $SUPX $HIT $TWOH $DTREF $AIBT 🚀 $SNYR: Major Distribution Breakthrough & Profit Surge Revenue: $9.1M (+33% YoY). Gross Margin Hit 77.8% (up from 72.1% YoY) industry-leading profitability. Net Income: $1.2M (+58% YoY). $HCWB $OSRH $OPAD" [X Link](https://x.com/FormalyTwilter/status/1960079265363640828) 2025-08-25T20:38Z [---] followers, [----] engagements "$ABCL [--]. T (TCEs) $ABCL T : PSMACD3 - - [--]. Safer T-cell engagers (TCEs) $ABCL designs cancer-fighting T-cells that minimize dangerous immune overreactions. Ex: PSMACD3 for prostate cancer targets tumors while sparing healthy tissue. Safer drugs - easier approvals - more partnerships. https://t.co/iwTHoVhWj8 [--]. Safer T-cell engagers (TCEs) $ABCL designs cancer-fighting T-cells that minimize dangerous immune overreactions. Ex: PSMACD3 for prostate cancer targets tumors while sparing healthy tissue. Safer drugs - easier approvals - more partnerships. https://t.co/iwTHoVhWj8" [X Link](https://x.com/FormalyTwilter/status/1960339450590028118) 2025-08-26T13:52Z [---] followers, [---] engagements "$ARDX AI Ardelyx 3-0 $ARDX AI predicts with confidence Ardelyx wins as witnessed by unanimous vote 3-0. We are so back. https://t.co/JSchIPPC1p $ARDX AI predicts with confidence Ardelyx wins as witnessed by unanimous vote 3-0. We are so back. https://t.co/JSchIPPC1p" [X Link](https://x.com/FormalyTwilter/status/1960342855974822017) 2025-08-26T14:05Z [---] followers, [---] engagements "$ABCL AbCellera ABCL575 Phase1 +2.03% $ABCL +2.03% today as AbCellera Doses First Participants in a Phase [--] Clinical Trial of ABCL575 More Info: https://t.co/8VcQirUjbP https://t.co/Q992USj9mE $ABCL +2.03% today as AbCellera Doses First Participants in a Phase [--] Clinical Trial of ABCL575 More Info: https://t.co/8VcQirUjbP https://t.co/Q992USj9mE" [X Link](https://x.com/FormalyTwilter/status/1960719414560760213) 2025-08-27T15:01Z [---] followers, [---] engagements "$ESPR 🍿 @MACROVET888 $ESPR Could be. Stage is set for major success this surely would be the time to try to steal the company before the price starts to really rise🍿 https://t.co/hLeqJQiqQZ @MACROVET888 $ESPR Could be. Stage is set for major success this surely would be the time to try to steal the company before the price starts to really rise🍿 https://t.co/hLeqJQiqQZ" [X Link](https://x.com/FormalyTwilter/status/1962193310489231418) 2025-08-31T16:38Z [---] followers, [---] engagements "$ESPR $ESPR Ignore the biotech games. Payday is coming https://t.co/HD2Ylcyk2F $ESPR Ignore the biotech games. Payday is coming https://t.co/HD2Ylcyk2F" [X Link](https://x.com/anyuser/status/1962197415265734725) 2025-08-31T16:54Z [---] followers, [---] engagements "# #OtsukaPharmaceutical $ESPR 2025829" [X Link](https://x.com/anyuser/status/1962200636508062165) 2025-08-31T17:07Z [---] followers, [---] engagements "#OtsukaPharmaceutical $ESPR [--] ( )" [X Link](https://x.com/anyuser/status/1962201366140682716) 2025-08-31T17:10Z [---] followers, [---] engagements "$HUMA $SENS http://patreon.com/Whatmarketmind http://patreon.com/Whatmarketmind" [X Link](https://x.com/anyuser/status/1962882947188670836) 2025-09-02T14:18Z [---] followers, [---] engagements "$SGMO $QURE $SGMO One more thought: $SGMO has repeatedly messaged that partners have interestbut worry about regulatory risk. With the FDA easing and $QURE clearly being YEARS from something close after basically needing to start over at lower dose (imo only based on SAEs in small sample) I think One more thought: $SGMO has repeatedly messaged that partners have interestbut worry about regulatory risk. With the FDA easing and $QURE clearly being YEARS from something close after basically needing to start over at lower dose (imo only based on SAEs in small sample) I think" [X Link](https://x.com/FormalyTwilter/status/1964018087440896479) 2025-09-05T17:29Z [---] followers, [---] engagements "$SGMO $QURE FDA $QURE SAE DD One more thought: $SGMO has repeatedly messaged that partners have interestbut worry about regulatory risk. With the FDA easing and $QURE clearly being YEARS from something close after basically needing to start over at lower dose (imo only based on SAEs in small sample) I think One more thought: $SGMO has repeatedly messaged that partners have interestbut worry about regulatory risk. With the FDA easing and $QURE clearly being YEARS from something close after basically needing to start over at lower dose (imo only based on SAEs in small sample) I think" [X Link](https://x.com/anyuser/status/1964018268735492203) 2025-09-05T17:30Z [---] followers, [----] engagements "#SPX #SP500 SP500 $ENPH ( Enphase Energy ) $CZR ( Caesars Entertainment ) $MKTX (Marketaxess Holdings ) SP00 $HOOD ( Robinhood Markets ) $APP ( Applovin Corp ) $EME ( EMCOR Group Inc )" [X Link](https://x.com/FormalyTwilter/status/1965786182652211203) 2025-09-10T14:35Z [---] followers, [---] engagements "$GLSI 📈 / Greenwich Lifesciences Inc 🕒 7:00 💥 +15.73% 🔍 Greenwich LifeSciences ( $GLSI ) GLSI-100 FDA 📈FOLLOW-UP /Impact after news alert Greenwich Lifesciences Inc $GLSI 🕒Time of detection: 7:00 AM (UTC-4) New York 💥Move: +15.73% 🔍News: Greenwich LifeSciences' GLSI-100 Granted US FDA Fast Track Designation ⚡ Follow us for real-time scalping alerts 📊Chart #Scalping https://t.co/vO1BMmJcuO 📈FOLLOW-UP /Impact after news alert Greenwich Lifesciences Inc $GLSI 🕒Time of detection: 7:00 AM (UTC-4) New York 💥Move: +15.73% 🔍News: Greenwich LifeSciences' GLSI-100 Granted US FDA Fast" [X Link](https://x.com/FormalyTwilter/status/1965878675821531245) 2025-09-10T20:42Z [---] followers, [---] engagements "$RNA $TRML DM1 FSHD ( ) $RNA Novartis strikes again After walking away from $cytk deal early '24 they may have done so again with Avidity. $trml yesterday may have been the tell. In any case before DM1 and FSHD pivotals reading out this was an impossible deal to close now. $RNA Novartis strikes again After walking away from $cytk deal early '24 they may have done so again with Avidity. $trml yesterday may have been the tell. In any case before DM1 and FSHD pivotals reading out this was an impossible deal to close now" [X Link](https://x.com/FormalyTwilter/status/1965887093294641586) 2025-09-10T21:16Z [---] followers, [---] engagements "$VERA Vera TherapeuticsIgAORIGIN346% $XBI $IBB $XPH $PPH https://pryzm.ozmosi.com/product/2843 $VERA Vera Therapeutics reports 46% decrease in proteinuria with Atacicept in ORIGIN Phase [--] study for adults with IgA nephropathy. More Info: https://t.co/GsNbxwNYuG $XBI $IBB $XPH $PPH https://t.co/PWapTmP6Oz https://pryzm.ozmosi.com/product/2843 $VERA Vera Therapeutics reports 46% decrease in proteinuria with Atacicept in ORIGIN Phase [--] study for adults with IgA nephropathy. More Info: https://t.co/GsNbxwNYuG $XBI $IBB $XPH $PPH https://t.co/PWapTmP6Oz" [X Link](https://x.com/FormalyTwilter/status/1967417321649271181) 2025-09-15T02:36Z [---] followers, [---] engagements "$ARQT Arcutis Biotherapeutics Inc. $ARQT Arcutis Biotherapeutics Inc. Data insight $ARQT: Computational framework detects fading impulse immediate dynamics + fundamental headwinds strategic positioning. Defensive strategies strongly favored over aggressive. $ARQT Arcutis Biotherapeutics Inc. Data insight $ARQT: Computational framework detects fading impulse immediate dynamics + fundamental headwinds strategic positioning. Defensive strategies strongly favored over aggressive" [X Link](https://x.com/FormalyTwilter/status/1978466487963943288) 2025-10-15T14:22Z [---] followers, [---] engagements "( ) $GEN +5 $CSCO +5 $FFIV +11 ( ) Cybersecurity Is Quietly Becoming the Most Powerful Growth Story in Tech The global cybersecurity market is now estimated between $225B$300B for [--------] making it one of the largest and fastest-growing segments in all of technology. According to Gartner end-user security https://t.co/rSfWUAcJZo Cybersecurity Is Quietly Becoming the Most Powerful Growth Story in Tech The global cybersecurity market is now estimated between $225B$300B for [--------] making it one of the largest and fastest-growing segments in all of technology. According to Gartner end-user" [X Link](https://x.com/FormalyTwilter/status/1978853989958537226) 2025-10-16T16:02Z [---] followers, [---] engagements "$CLLN Clene Inc CNM-Au8" [X Link](https://x.com/FormalyTwilter/status/1983248663041454513) 2025-10-28T19:05Z [---] followers, [---] engagements "$NRSN ALS PrimeC Phase3 FDA NeuroSense Receives FDA Clearance to Initiate Pivotal Phase [--] Trial for PrimeC in ALS $NRSN https://t.co/IlKLl5JfXd NeuroSense Receives FDA Clearance to Initiate Pivotal Phase [--] Trial for PrimeC in ALS $NRSN https://t.co/IlKLl5JfXd" [X Link](https://x.com/FormalyTwilter/status/1993076715476976042) 2025-11-24T21:58Z [---] followers, [---] engagements "$PLX $ION $GERN - $PLX $IOVA $GERN- Appreciated David sharing a few of his options income trades to finish out the year Love it when ppl make my framework their own/ incorporate into their system & strategy https://t.co/e7z43BPaRu $PLX $IOVA $GERN- Appreciated David sharing a few of his options income trades to finish out the year Love it when ppl make my framework their own/ incorporate into their system & strategy https://t.co/e7z43BPaRu" [X Link](https://x.com/FormalyTwilter/status/2003833919595254126) 2025-12-24T14:23Z [---] followers, [---] engagements "SNDX $KURA / $NUVB $NUVL :) KMT2A 2026-2028 + NPM1 + $SNDX $KURA $NUVB $NUVL @Andre_AGTC @develiforever it will :) Maintenance setting for KMT2A kicking in 2026-2028 + NPM1 +off label combos earlier line $SNDX $KURA Re $NUVB doubt you will see $NUVL catch up in frontline for quite a few years But again opinions are what make markets Hope [----] is your best year yet my friend @Andre_AGTC @develiforever it will :) Maintenance setting for KMT2A kicking in 2026-2028 + NPM1 +off label combos earlier line $SNDX $KURA Re $NUVB doubt you will see $NUVL catch up in frontline for quite a few years But" [X Link](https://x.com/FormalyTwilter/status/2007109304097407310) 2026-01-02T15:18Z [---] followers, [---] engagements "$RGNX Regenxbio [------] Clemidsogenelanparvovec Phase3 II https://pryzm.ozmosi.com/product/25156 $RGNX Regenxbio presented Phase [--] Mucopolysaccharidosis II results on 2025-09-05 for Clemidsogene lanparvovec More Info: https://t.co/8yqji8GXR3 https://t.co/wyuyE6gYJ8 https://pryzm.ozmosi.com/product/25156 $RGNX Regenxbio presented Phase [--] Mucopolysaccharidosis II results on 2025-09-05 for Clemidsogene lanparvovec More Info: https://t.co/8yqji8GXR3 https://t.co/wyuyE6gYJ8" [X Link](https://x.com/FormalyTwilter/status/2007198696371519592) 2026-01-02T21:13Z [---] followers, [---] engagements "$RGNX @REGENXBIO Prospects for @REGENXBIO's clemidsogene lanparvovec approval in Hunter syndrome https://t.co/d6TzXxOP0p Prospects for @REGENXBIO's clemidsogene lanparvovec approval in Hunter syndrome https://t.co/d6TzXxOP0p" [X Link](https://x.com/FormalyTwilter/status/2007199339060609368) 2026-01-02T21:16Z [---] followers, [---] engagements "$XFOR $XFOR $4.23$4.50 $5 $XFOR: XFOR defended $4.23; reclaim $4.50 and youre back in trend-rebuild mode. Options lens: $5 is the key strike to watch if momentum flips. $XFOR: XFOR defended $4.23; reclaim $4.50 and youre back in trend-rebuild mode. Options lens: $5 is the key strike to watch if momentum flips" [X Link](https://x.com/FormalyTwilter/status/2009001309928861989) 2026-01-07T20:36Z [---] followers, [--] engagements "$AQST - FDA NDA $AQST $SPRY CRL [--] ( ) $AQST - The company said that the FDA has found deficiencies in the NDA. AQST did not list any specifics. This is the advantage of having the Fast Track designation. I believe it will be worked out. Remember what happened to $SPRY even with CRL the price recovered within [--] $AQST - The company said that the FDA has found deficiencies in the NDA. AQST did not list any specifics. This is the advantage of having the Fast Track designation. I believe it will be worked out. Remember what happened to $SPRY even with CRL the price recovered within 4" [X Link](https://x.com/FormalyTwilter/status/2009634857190920309) 2026-01-09T14:34Z [---] followers, [---] engagements "1/9 ( ) $MPLT 3% $CATX 2% 212Pb VMT--NET $INKT 2% AgenT-797 [--] 📌 Biotech Stock News 1/9 @ Open $CGON 21% Updated Timeline for PIVOT-006 Data $PDSB 15% FDA Alignment on PFS as Endpoint $IBIO 14% $26M Private Placement $QURE 14% Type A Meeting Scheduled with FDA $KRYS 5% Positive Interim Clinical Update on KB407 $MPLT 3% Topline Results https://t.co/Dktelv9F3X 📌 Biotech Stock News 1/9 @ Open $CGON 21% Updated Timeline for PIVOT-006 Data $PDSB 15% FDA Alignment on PFS as Endpoint $IBIO 14% $26M Private Placement $QURE 14% Type A Meeting Scheduled with FDA $KRYS 5% Positive Interim Clinical" [X Link](https://x.com/FormalyTwilter/status/2009675227979231396) 2026-01-09T17:14Z [---] followers, [---] engagements "$GLUE 50% 📈 MGD MRT-8102 hsCRP 94% hsCRP [--] mg/L (1 Phase [--] 👇 https://offers.bpiq.com/big-mover-lpmo=jun $GLUE up 50% 📈 Oral MGD MRT-8102 shows rapid hsCRP reduction 94% of patients suppressed to [--] mg/L hsCRP Biologic-like efficacy with no SAEs reported (Phase 1) Dont miss out on future Big Movers Access our FREE Big Mover Report 👇 https://t.co/g8sMZ9xwJM https://offers.bpiq.com/big-mover-lpmo=jun $GLUE up 50% 📈 Oral MGD MRT-8102 shows rapid hsCRP reduction 94% of patients suppressed to [--] mg/L hsCRP Biologic-like efficacy with no SAEs reported (Phase 1) Dont miss out on future Big" [X Link](https://x.com/FormalyTwilter/status/2010834402218012748) 2026-01-12T22:00Z [---] followers, [---] engagements "$RGNX PDUFA : ( [------] ) / RGX-121 / RGX-121 MPS II CNS AAV9 ( ) $RGNX (February [--] 2026) RGX-121 / Hunter syndrome / PDUFA Why RGX-121 is different One-time CNS AAV9 gene therapy targeting the genetic cause of neuronopathic MPS II. Pivotal CAMPSIITE signal Primary endpoint met; CSF HS D2S6 82% through 1Y (80% maintained) https://t.co/BJZtSHngUH $RGNX (February [--] 2026) RGX-121 / Hunter syndrome / PDUFA Why RGX-121 is different One-time CNS AAV9 gene therapy targeting the genetic cause of neuronopathic MPS II. Pivotal CAMPSIITE signal Primary endpoint met; CSF HS D2S6 82% through 1Y (80%" [X Link](https://x.com/FormalyTwilter/status/2011420072255086833) 2026-01-14T12:48Z [---] followers, [---] engagements "$RGNX PDUFA : ( [------] ) / RGX-121 / CAMPSIITE HS D2S6 182%80% [--] BSID-III [--] HS D2S6 1r [-----] $RGNX (February [--] 2026) RGX-121 / Hunter syndrome / PDUFA Why RGX-121 is different One-time CNS AAV9 gene therapy targeting the genetic cause of neuronopathic MPS II. Pivotal CAMPSIITE signal Primary endpoint met; CSF HS D2S6 82% through 1Y (80% maintained) https://t.co/BJZtSHngUH $RGNX (February [--] 2026) RGX-121 / Hunter syndrome / PDUFA Why RGX-121 is different One-time CNS AAV9 gene therapy targeting the genetic cause of neuronopathic MPS II. Pivotal CAMPSIITE signal Primary endpoint met; CSF HS" [X Link](https://x.com/FormalyTwilter/status/2011420301993836799) 2026-01-14T12:49Z [---] followers, [---] engagements "$AMIX $TOON $SOAR $SJ $BNRG $PNPNF $PRSO [--] [-----] #ShortSqueeze #TechStocks #Momentum #BreakoutStocks #StocksToWatch #SmallCaps #WallStreetToBayStreet https://thestreetreports.com/stocks-under-1-amix-toon-soar-sj-bnrg-pnpnf-prso-double-digit-2026-watchlist/ Stocks Under $1: $AMIX $TOON $SOAR $SJ $BNRG $PNPNF $PRSO Double-Digit [----] Watchlist https://t.co/7j44LAakYg #ShortSqueeze #TechStocks #Momentum #BreakoutStocks #StocksToWatch #SmallCaps #WallStreetToBayStreet https://thestreetreports.com/stocks-under-1-amix-toon-soar-sj-bnrg-pnpnf-prso-double-digit-2026-watchlist/ Stocks Under $1: $AMIX" [X Link](https://x.com/FormalyTwilter/status/2011461844100383001) 2026-01-14T15:34Z [---] followers, [---] engagements "$CMMB $CMMB VWAP $CMMB needs to break this general downtrend. Keeping it on watch for potential reversal and VWAP test. https://t.co/w75dzHy5LM $CMMB needs to break this general downtrend. Keeping it on watch for potential reversal and VWAP test. https://t.co/w75dzHy5LM" [X Link](https://x.com/FormalyTwilter/status/2012205201998913779) 2026-01-16T16:47Z [---] followers, [--] engagements "$ANRO #ALTO-100 ALTO-100 ( )" [X Link](https://x.com/FormalyTwilter/status/2013349748590420224) 2026-01-19T20:36Z [---] followers, [--] engagements "$ANRO #ALTO-100 ( ) ALTO-100 PhaseIIb" [X Link](https://x.com/FormalyTwilter/status/2013350615662108914) 2026-01-19T20:39Z [---] followers, [--] engagements "$ANRO #ALTO-101 ( ) Phase2 ALTO-101 EEG" [X Link](https://x.com/FormalyTwilter/status/2013355193400992112) 2026-01-19T20:57Z [---] followers, [--] engagements "$OGN : P/E [---] ( $2.4B) $CRMD : P/E [---] ( $592M) $ABEO : P/E [---] ( $287M) Not every biotech is trading at hype-level valuations. Some have massive valuation reset potential: $OGN: P/E [---] (mkt cap. $2.4B) $CRMD: P/E [---] (mkt cap. $592M) $ABEO: P/E [---] (mkt cap. $287M) Low multiples can often be found in small caps. Not every biotech is trading at hype-level valuations. Some have massive valuation reset potential: $OGN: P/E [---] (mkt cap. $2.4B) $CRMD: P/E [---] (mkt cap. $592M) $ABEO: P/E [---] (mkt cap. $287M) Low multiples can often be found in small caps" [X Link](https://x.com/FormalyTwilter/status/2014704318952439935) 2026-01-23T14:18Z [---] followers, [---] engagements "$UTHR 🧬 UnitedTherapeutics MiroliverELAP Phase1 - ✅ 100% ✅ ➡ Phase2 : https://ir.unither.com//media/Files/U/United-Therapeutics-IR/documents/press-releases/2026/press-release-miroliverelap-phase-1-results.pdf 🧬 United Therapeutics ( $UTHR) hls spch v [--]. fzi studie miroliverELAP prvnch bioinenrsky vytvoench jater na svt. ✅ 100% peit u testovanch pacient ✅ dn vn vedlej inky ➡Smr [--]. fze Zdroj: https://t.co/BHfPmAHYSy https://ir.unither.com//media/Files/U/United-Therapeutics-IR/documents/press-releases/2026/press-release-miroliverelap-phase-1-results.pdf 🧬 United Therapeutics ( $UTHR) hls spch" [X Link](https://x.com/FormalyTwilter/status/2016097343129657376) 2026-01-27T10:33Z [---] followers, [--] engagements "$RHHBY GLP-1/GIP CT-388 Phase2 $LLY $NVO $VKTX $RHHBY Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity. $LLY $NVO $VKTX https://t.co/k6KIIIUF8I $RHHBY Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity. $LLY $NVO $VKTX https://t.co/k6KIIIUF8I" [X Link](https://x.com/FormalyTwilter/status/2016103232540704849) 2026-01-27T10:57Z [---] followers, [---] engagements "$ASPI $QLE $SKBL $QLE IPO HALEU ( ) $ASPI $QLE $SKBL Graphic we recently put together to help better understand how these companies connect. $QLE will be interesting to see how IPO and HALEU deadlines pan out. TerraPower made it clear $ASPI was the only company who could meet their timeline and demand. https://t.co/suZSl9Ok1p $ASPI $QLE $SKBL Graphic we recently put together to help better understand how these companies connect. $QLE will be interesting to see how IPO and HALEU deadlines pan out. TerraPower made it clear $ASPI was the only company who could meet their timeline and demand." [X Link](https://x.com/FormalyTwilter/status/2017234686771441905) 2026-01-30T13:53Z [---] followers, [---] engagements "$GUTS Fractyl Health Revita FDA PMA DeNovo [--] FDA [-----] ( ) $GUTS Fractyl Health shares sank to a 52week low as it may shift Revitas FDA path from PMA to De Novo; FDA feedback due Q2 [----]. In REMAIN1 Revita cut postGLP1 weight regain (4.5% vs 7.5% at [--] months) with good safety; 12month data Q3 [----]. $GUTS Fractyl Health shares sank to a 52week low as it may shift Revitas FDA path from PMA to De Novo; FDA feedback due Q2 [----]. In REMAIN1 Revita cut postGLP1 weight regain (4.5% vs 7.5% at [--] months) with good safety; 12month data Q3 2026" [X Link](https://x.com/FormalyTwilter/status/2017282219468018096) 2026-01-30T17:02Z [---] followers, [---] engagements "$CAPR FDA HOPE-3 Deramiocel BLA 🧬 DMD 📈 $CAPR just provided a major regulatory update on the Deramiocel BLA following FDA review of HOPE-3 data. 🧬 The market is laser-focused on the DMD approval timeline. Is the path to commercialization fully de-risked or are we facing a "delay-trap" 📈 $CAPR just provided a major regulatory update on the Deramiocel BLA following FDA review of HOPE-3 data. 🧬 The market is laser-focused on the DMD approval timeline. Is the path to commercialization fully de-risked or are we facing a "delay-trap" 📈" [X Link](https://x.com/FormalyTwilter/status/2018395444519501836) 2026-02-02T18:45Z [---] followers, [---] engagements "$TLPH CRRT [--] 🧵 $TLPH Nafamostat cant compete with heparin because heparin is cheap and established imo. That leaves the other [--] % of CRRT market competing against citrate and no anticoagulation. 🧵 $TLPH Nafamostat cant compete with heparin because heparin is cheap and established imo. That leaves the other [--] % of CRRT market competing against citrate and no anticoagulation. 🧵" [X Link](https://x.com/FormalyTwilter/status/2018810845879587301) 2026-02-03T22:16Z [---] followers, [--] engagements "$TLPH CRRT Citrate is expensive complex and is barely used in US. Docs rather not anticoagulate at all and pay for extra CRRT filters that clot more frequently due to no anticoagulation. Citrate is expensive complex and is barely used in US. Docs rather not anticoagulate at all and pay for extra CRRT filters that clot more frequently due to no anticoagulation" [X Link](https://x.com/FormalyTwilter/status/2018811252068560944) 2026-02-03T22:18Z [---] followers, [--] engagements "$TLPH CRRT ( ) So real competition for nafamostat is no anticoagulation. Commercial incentive to anticoagulate is prolonging CRRT filter life. Nafamostat will likely double filter life so hospitals will need half as many filters if they use nafamostat. One filter is $500. So real competition for nafamostat is no anticoagulation. Commercial incentive to anticoagulate is prolonging CRRT filter life. Nafamostat will likely double filter life so hospitals will need half as many filters if they use nafamostat. One filter is $500" [X Link](https://x.com/FormalyTwilter/status/2018812103788990503) 2026-02-03T22:21Z [---] followers, [--] engagements "$TLPH ( ) [---] So real competition for nafamostat is no anticoagulation. Commercial incentive to anticoagulate is prolonging CRRT filter life. Nafamostat will likely double filter life so hospitals will need half as many filters if they use nafamostat. One filter is $500. So real competition for nafamostat is no anticoagulation. Commercial incentive to anticoagulate is prolonging CRRT filter life. Nafamostat will likely double filter life so hospitals will need half as many filters if they use nafamostat. One filter is $500" [X Link](https://x.com/FormalyTwilter/status/2018812367979917616) 2026-02-03T22:22Z [---] followers, [--] engagements "$TLPH [---] [---------] ( ) [--] million filters used in US per year. By using nafamostat vs no anticoagulation hospitals would need 300-400 thousand filters less so $175 million in cost savings per year. So $tlph peak sales estimate $200 mil seems realistic depending on final numbers of filter life. [--] million filters used in US per year. By using nafamostat vs no anticoagulation hospitals would need 300-400 thousand filters less so $175 million in cost savings per year. So $tlph peak sales estimate $200 mil seems realistic depending on final numbers of filter life" [X Link](https://x.com/FormalyTwilter/status/2018812810437022064) 2026-02-03T22:24Z [---] followers, [---] engagements "$TLPH ( ) $TLPH [--] [--] million filters used in US per year. By using nafamostat vs no anticoagulation hospitals would need 300-400 thousand filters less so $175 million in cost savings per year. So $tlph peak sales estimate $200 mil seems realistic depending on final numbers of filter life. [--] million filters used in US per year. By using nafamostat vs no anticoagulation hospitals would need 300-400 thousand filters less so $175 million in cost savings per year. So $tlph peak sales estimate $200 mil seems realistic depending on final numbers of filter life" [X Link](https://x.com/FormalyTwilter/status/2018813070861378035) 2026-02-03T22:25Z [---] followers, [---] engagements "@cluelessbio $TLPH" [X Link](https://x.com/FormalyTwilter/status/2018813913933172774) 2026-02-03T22:28Z [---] followers, [--] engagements "$TLPH $CRMD [--] $TLPH $CRMD ( ) https://x.com/BussinBiotech/status/1899912549551783956 Back in March I highlighted the connection between $TLPH and $CRMD well before the private placements and strategic investments were announced publicly later in the year. https://t.co/KGp8z7HhgZ I fully expect my thesis to continue to play out culminating in a full https://x.com/BussinBiotech/status/1899912549551783956 Back in March I highlighted the connection between $TLPH and $CRMD well before the private placements and strategic investments were announced publicly later in the year." [X Link](https://x.com/FormalyTwilter/status/2018819793026265306) 2026-02-03T22:52Z [---] followers, [---] engagements "$TLPH $CRMD [----] $CRMD $TLPH [----] Back in March I highlighted the connection between $TLPH and $CRMD well before the private placements and strategic investments were announced publicly later in the year. https://t.co/KGp8z7HhgZ I fully expect my thesis to continue to play out culminating in a full Back in March I highlighted the connection between $TLPH and $CRMD well before the private placements and strategic investments were announced publicly later in the year. https://t.co/KGp8z7HhgZ I fully expect my thesis to continue to play out culminating in a full" [X Link](https://x.com/FormalyTwilter/status/2018820072077471919) 2026-02-03T22:53Z [---] followers, [---] engagements Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@FormalyTwilter 佐藤雄二
佐藤雄二 posts on X about $qure, $aspi, $tlph, $xbi the most. They currently have [---] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.
Engagements: [-----] #
- [--] Week [------] +1,558,800%
- [--] Month [------] +1,955%
- [--] Months [------] +818%
Mentions: [--] #
- [--] Months [--] -5.30%
Followers: [---] #
- [--] Week [---] +0.64%
- [--] Month [---] +4%
- [--] Months [---] +0.21%
CreatorRank: [---------] #
Social Influence
Social category influence stocks 53.15% finance 15.38% cryptocurrencies 8.39% countries 3.5% financial services #613 technology brands 2.1% social networks 0.7% exchanges 0.7%
Social topic influence $qure 7.69%, $aspi #6, $tlph 6.29%, $xbi #52, $vnda #7, $nktr #79, $eton 4.9%, eton 4.9%, more info #1869, stocks #3853
Top accounts mentioned or mentioned by @mmatters22596 @stocknear @aleabitoreddit @biotechautist @asamimes @brianskorney @leerinkpartners @clearstreetnews @biotech2k1 @colemana64 @teradasyacho @macrovet888 @andreagtc @develiforever @regenxbio @regenxbios @cluelessbio @zethedeuce
Top assets mentioned uniQure N.V. (QURE) ASP Isotopes Inc. (ASPI) Huma Finance (HUMA) Kymera Therapeutics, Inc. (KYMR) Alto Neuroscience, Inc. (ANRO) Tyra Biosciences, Inc. (TYRA) Skyline Builders Group Holding Limited (SKBL) Eli Lilly and Company (LLY) Sarepta Therapeutics, Inc. (SRPT) Goldman Sachs (GS) Duolingo, Inc. (DUOL) Apogee Therapeutics, Inc. (APGE) Nuvation Bio Inc. (NUVB) Vertex Protocol (VRTX) Origin Protocol (OGN) Agios Pharmaceuticals, Inc. (AGIO) Wave Life Sciences Ltd. Ordinary Shares (WVE) Biofrontera Inc. (BFRI) Aardvark Therapeutics, Inc (AARD) Evommune, Inc. (EVMN) Novo-Nordisk (NVO) Cytokinetics Inc. (CYTK) Enphase Energy Inc (ENPH) AbCellera Biologics Inc. (ABCL) Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Amgen, Inc. (AMGN) Merck & Co., Inc. (MRK) GammaSwap (GS) Reddit, Inc. (RDDT) Axsome Therapeutics, Inc (AXSM) Turn Therapeutics, Inc. (TTRX) Hims & Hers Health, Inc. (HIMS) SoFi Technologies, Inc. Common Stock (SOFI)
Top Social Posts
Top posts by engagements in the last [--] hours
"$AGIO 400060% [----] [--] @stocknear There are [----] patients of thalassemia in USA . [--] percent are transfusion dependent. So at this price revenue should easily cross a billion dollars in USA alone in about [--] months.The market cap is [---] billion. Stock should easily double from here. @stocknear There are [----] patients of thalassemia in USA . [--] percent are transfusion dependent. So at this price revenue should easily cross a billion dollars in USA alone in about [--] months.The market cap is [---] billion. Stock should easily double from here"
X Link 2026-02-04T16:32Z [---] followers, [---] engagements
"$AGIO AgiosPharmaceuticals FDA AQVESME AQVESME [-------] $AGIO Agios Pharmaceuticals shares are trading higher after the company announced the FDA approved AQVESME for the treatment of anemia in adults with alpha- or beta-thalassemia. An exect announced AQVESME will be introduce at approximately $425000 per patient per year. $AGIO Agios Pharmaceuticals shares are trading higher after the company announced the FDA approved AQVESME for the treatment of anemia in adults with alpha- or beta-thalassemia. An exect announced AQVESME will be introduce at approximately $425000 per patient per year"
X Link 2026-02-04T16:36Z [---] followers, [---] engagements
"$MDGL [--] siRNA MASH [------] http://SuzhouRiboLifeScienceCo.Ltd $MDGL Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs with Suzhou Ribo Life Science Co. Lt US $60 million Upfront and cumulative payments across the programs could reach US $4.4 billion https://t.co/hYvsykdfgp http://SuzhouRiboLifeScienceCo.Ltd $MDGL Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs with Suzhou Ribo Life Science Co. Lt US $60 million Upfront and cumulative payments across the programs could"
X Link 2026-02-11T14:04Z [---] followers, [---] engagements
"$SKBL $SKBL [--] Panamax 220DOE DOE LPO60-70% IP $ASPI #SKBL #Uranium Mandatory listen for all $SKBL investors: 2.2m lbs of uranium per year from [--] Panamax deployment. DOE tech. Supporting US domestic uranium supply. Highly confident about DOE LPO loan. Would cover 60-70% capex. Developing IP for suite of other metals. $ASPI Mandatory listen for all $SKBL investors: 2.2m lbs of uranium per year from [--] Panamax deployment. DOE tech. Supporting US domestic uranium supply. Highly confident about DOE LPO loan. Would cover 60-70% capex. Developing IP for suite of other metals. $ASPI"
X Link 2026-02-02T10:36Z [---] followers, [----] engagements
"$QURE - FDA 150% vs 30% $QURE AMT-130 AA $CLPT $CLPT [--] $QURE potential stock moving catalyst- FDA meeting updates Potential upside 150% vs downside 30% Another stock that would surge big is $CLPT if $QURE gets the AA for AMT-130 $CLPT could more than double on positive news because it will be the confirmatory evidence for the $QURE potential stock moving catalyst- FDA meeting updates Potential upside 150% vs downside 30% Another stock that would surge big is $CLPT if $QURE gets the AA for AMT-130 $CLPT could more than double on positive news because it will be the confirmatory evidence for"
X Link 2026-02-04T16:49Z [---] followers, [---] engagements
"$QURE $QURE $CLPT $QURE potential stock moving catalyst- FDA meeting updates Potential upside 150% vs downside 30% Another stock that would surge big is $CLPT if $QURE gets the AA for AMT-130 $CLPT could more than double on positive news because it will be the confirmatory evidence for the $QURE potential stock moving catalyst- FDA meeting updates Potential upside 150% vs downside 30% Another stock that would surge big is $CLPT if $QURE gets the AA for AMT-130 $CLPT could more than double on positive news because it will be the confirmatory evidence for the"
X Link 2026-02-04T16:50Z [---] followers, [----] engagements
"$NKTR $QURE ( ) Catalist Actually I decided to start the fun early. Bot some $NKTR calls for maintenance data play and $QURE calls for FDA Type A meeting minutes play. Both fairly uncorrelated with broader market and charts look decent for bottom fishing with appropriate catalysts in place before my https://t.co/1tBX30s0Ae Actually I decided to start the fun early. Bot some $NKTR calls for maintenance data play and $QURE calls for FDA Type A meeting minutes play. Both fairly uncorrelated with broader market and charts look decent for bottom fishing with appropriate catalysts in place before"
X Link 2026-02-04T20:40Z [---] followers, [----] engagements
"$LLY ( EliLilly )2026 Even with pricing headwinds Eli Lilly expects sales surge to continue in [----] https://t.co/AYFOXbf9NR Even with pricing headwinds Eli Lilly expects sales surge to continue in [----] https://t.co/AYFOXbf9NR"
X Link 2026-02-04T20:51Z [---] followers, [--] engagements
"#FDA $AMGN #Amgen FDA Phase3 Amgen Tavneos - - FDA rehashing old Ph3 data and seeking to withdrawal of Amgen's Tavneos but company says it won't pull drug - very weird very unprecedented - https://t.co/trwypcvk6Z FDA rehashing old Ph3 data and seeking to withdrawal of Amgen's Tavneos but company says it won't pull drug - very weird very unprecedented - https://t.co/trwypcvk6Z"
X Link 2026-02-04T21:39Z [---] followers, [---] engagements
"$ASPI PDRadiopharma PSMA *1 mCRPC 177Lu-PSMA-I&T Curium today announced that together with PeptiDream and PDRadiopharma the first patient has been dosed in the companies registrational clinical trial of 177Lu-PSMA-I&T in Japan for patients with PSMA (*1)-positive metastatic castration-resistant prostate cancer (mCRPC) $ASPI https://t.co/Anw7EPIg7l Curium today announced that together with PeptiDream and PDRadiopharma the first patient has been dosed in the companies registrational clinical trial of 177Lu-PSMA-I&T in Japan for patients with PSMA (*1)-positive metastatic"
X Link 2026-02-05T09:47Z [---] followers, [----] engagements
"$SRPT $SRPT SRP-1005 $QURE $SRPT Announces Approval of Clinical Trial Application for SRP-1005 Its Investigational Treatment for Huntingtons Disease. $QURE https://t.co/vhXhb1HcMw $SRPT Announces Approval of Clinical Trial Application for SRP-1005 Its Investigational Treatment for Huntingtons Disease. $QURE https://t.co/vhXhb1HcMw"
X Link 2026-02-05T09:58Z [---] followers, [----] engagements
"$QURE 10:30 $QURE [----] tomorrow. Thats when we get data $QURE [----] tomorrow. Thats when we get data"
X Link 2026-02-06T20:22Z [---] followers, [---] engagements
"$QURE AMT-191 $QURE ( ) AMT-191 active drug dose-limiting toxicity (liver enzymes) but seems manageable. $QURE have to collect more data to substantiate the long-term medical benefits with an acceptable safety profile. Early solid data but no home run. Short term the FDA feedback on HD will be key. https://t.co/4A3R2vip6X AMT-191 active drug dose-limiting toxicity (liver enzymes) but seems manageable. $QURE have to collect more data to substantiate the long-term medical benefits with an acceptable safety profile. Early solid data but no home run. Short term the FDA feedback on HD will be"
X Link 2026-02-06T20:42Z [---] followers, [---] engagements
"$QURE ( ) HD FDA AMT-191 active drug dose-limiting toxicity (liver enzymes) but seems manageable. $QURE have to collect more data to substantiate the long-term medical benefits with an acceptable safety profile. Early solid data but no home run. Short term the FDA feedback on HD will be key. https://t.co/4A3R2vip6X AMT-191 active drug dose-limiting toxicity (liver enzymes) but seems manageable. $QURE have to collect more data to substantiate the long-term medical benefits with an acceptable safety profile. Early solid data but no home run. Short term the FDA feedback on HD will be key."
X Link 2026-02-06T20:43Z [---] followers, [---] engagements
"$WVE CantorFitzgerald Webinar $WVE WV-007 [-----] - - BMI100 $WVE: Listening to the Cantor Fitzgerald webinar with $WVE management. WV-007 data coming up is very impressive and they're excited. Confirmed it will be in Q1 [----]. -Great differentiated data. -Accelerating higher BMI fully enrolled study w/ [---] patients. $WVE: Listening to the Cantor Fitzgerald webinar with $WVE management. WV-007 data coming up is very impressive and they're excited. Confirmed it will be in Q1 [----]. -Great differentiated data. -Accelerating higher BMI fully enrolled study w/ [---] patients"
X Link 2026-02-07T07:04Z [---] followers, [---] engagements
"$EIKN 200IPO $MRK 10% $XBI $IBB $EIKN Director acquires $2 million bucks at open market Fresh ipo. $MRK also took at 10% stake $XBI $IBB https://t.co/QlTNpPu5Ap $EIKN Director acquires $2 million bucks at open market Fresh ipo. $MRK also took at 10% stake $XBI $IBB https://t.co/QlTNpPu5Ap"
X Link 2026-02-07T07:21Z [---] followers, [---] engagements
"#SPX #Stocks S&P500 CTA STOCK SELL-OFF NOT OVER GOLDMAN TRADERS SAY Goldman Sachs warns that US stocks could face more selling this week driven by trend-following funds known as CTAs which have already hit sell triggers in the S&P [---]. The bank estimates CTAs could dump up to $33 billion this week STOCK SELL-OFF NOT OVER GOLDMAN TRADERS SAY Goldman Sachs warns that US stocks could face more selling this week driven by trend-following funds known as CTAs which have already hit sell triggers in the S&P [---]. The bank estimates CTAs could dump up to $33 billion this week"
X Link 2026-02-08T20:36Z [---] followers, [---] engagements
"#SPX #Stocks $GS CTA [---] - S&P500 [---] STOCK SELL-OFF NOT OVER GOLDMAN TRADERS SAY Goldman Sachs warns that US stocks could face more selling this week driven by trend-following funds known as CTAs which have already hit sell triggers in the S&P [---]. The bank estimates CTAs could dump up to $33 billion this week STOCK SELL-OFF NOT OVER GOLDMAN TRADERS SAY Goldman Sachs warns that US stocks could face more selling this week driven by trend-following funds known as CTAs which have already hit sell triggers in the S&P [---]. The bank estimates CTAs could dump up to $33 billion this week"
X Link 2026-02-08T20:39Z [---] followers, [---] engagements
"@aleabitoreddit $RDDT"
X Link 2026-02-09T12:38Z [---] followers, [---] engagements
"$AXSM [--] $AXSM ADA [---] PDUFA More unusual $AXSM options activity for February and March. Someone betting that a potential buyout happens before the April 30th PDUFA for ADA https://t.co/Lk3eAThcnk More unusual $AXSM options activity for February and March. Someone betting that a potential buyout happens before the April 30th PDUFA for ADA https://t.co/Lk3eAThcnk"
X Link 2026-02-09T12:51Z [---] followers, [---] engagements
"$ETON 2026-02-09 : $14.76 PDUFA : 2026-02-25 ET-600 ( ( ) ) PoA: 85% 2026-02-25 $ETON 14.76$ PDUFA Date ET-600 PoA: 85% 2026-02-25 $ETON 14.76$ PDUFA Date ET-600 PoA: 85%"
X Link 2026-02-09T14:27Z [---] followers, [--] engagements
"$ETON Catalist - 2026-02-25 - ET-600 - PoA85% https://biopharmawatch.com/company/ETON $ETON https://t.co/lwNT8GmOXU Catalyst Date - 2026-02-25 Drug - ET-600 (desmopressin oral solution) Treatment - central diabetes insipidus Poa : 85% https://biopharmawatch.com/company/ETON $ETON https://t.co/lwNT8GmOXU Catalyst Date - 2026-02-25 Drug - ET-600 (desmopressin oral solution) Treatment - central diabetes insipidus Poa : 85%"
X Link 2026-02-09T14:30Z [---] followers, [---] engagements
"$ETON [---] ( 200DMA ) Eton pharma $eton new rare disease drug upcoming. Chart not far from breakout. We are below 200D so quarterly results better be good. https://t.co/zYWKjIkOE8 Eton pharma $eton new rare disease drug upcoming. Chart not far from breakout. We are below 200D so quarterly results better be good. https://t.co/zYWKjIkOE8"
X Link 2026-02-09T14:34Z [---] followers, [--] engagements
"$ETON +3.75% EtonPharmaceuticals [---] FDA [----] https://notreload.xyz/eton-pharma-licenses-first-generic-ultra-rare-disease-drug/ $ETON +3.75% Eton Pharmaceuticals licenses U.S. rights to an ultra-rare disease treatment affecting under [---] patients expecting FDA approval and mid-2026 launch as first generic alternative. https://t.co/TRnDNA9ZxD https://t.co/h6ZQbBJrLH https://notreload.xyz/eton-pharma-licenses-first-generic-ultra-rare-disease-drug/ $ETON +3.75% Eton Pharmaceuticals licenses U.S. rights to an ultra-rare disease treatment affecting under [---] patients expecting FDA approval and"
X Link 2026-02-09T14:37Z [---] followers, [--] engagements
"$ETON $ETON Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate https://t.co/9B4jYttsJn $ETON Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate https://t.co/9B4jYttsJn"
X Link 2026-02-09T14:39Z [---] followers, [--] engagements
"$BFRI - Phase3 Ameluz 85%12% sNDA [-----] Catalist $BFRI - Phase [--] Ameluz results are in 85% complete response rate but stock's down 12% today. sNDA submission planned for Q3 [----] that's the next catalyst. $BFRI - Phase [--] Ameluz results are in 85% complete response rate but stock's down 12% today. sNDA submission planned for Q3 [----] that's the next catalyst"
X Link 2026-02-09T14:46Z [---] followers, [---] engagements
"$TTRX - GX-03 Phase2 FDA Medline/MiMedx [----] 6.5% Phase3 [----] $TTRX - GX-03 Phase [--] hits FDA clears path 70M+ partnership with Medline/MiMedx is a nice boost. Still stock's down 6.5% today maybe due to high expectations. Phase [--] for eczema and onychomycosis is next slated for [----]. $TTRX - GX-03 Phase [--] hits FDA clears path 70M+ partnership with Medline/MiMedx is a nice boost. Still stock's down 6.5% today maybe due to high expectations. Phase [--] for eczema and onychomycosis is next slated for 2027"
X Link 2026-02-09T14:48Z [---] followers, [--] engagements
"$HUMA Humacyte DOD [----] $Huma #Israel #Iran #Ukraine http://investors.humacyte.com/news-releases/news-release-details/humacyte-announces-new-us-department-defense-funding-procurement/ Humacyte announced DOD funding. Plus they have filed to be able to sell in Isreal should be approved in next 60-90 days or faster. $Huma #Israel #Iran #Ukraine https://t.co/1psvbFahOa https://t.co/hwzljqLJLe http://investors.humacyte.com/news-releases/news-release-details/humacyte-announces-new-us-department-defense-funding-procurement/ Humacyte announced DOD funding. Plus they have filed to be able to sell in"
X Link 2026-02-09T15:11Z [---] followers, [---] engagements
"$HUMA $HUMA DOD 12% $HUMA surges 12% on DOD funding for its bioengineered vessels but the numbers demand caution: This is a speculative move on a procurement bill not revenue. Wait for real confirmation before trading the volatility. https://t.co/3j6bWJ9vyS $HUMA surges 12% on DOD funding for its bioengineered vessels but the numbers demand caution: This is a speculative move on a procurement bill not revenue. Wait for real confirmation before trading the volatility. https://t.co/3j6bWJ9vyS"
X Link 2026-02-09T15:13Z [---] followers, [---] engagements
"$DUOL $HIMS 80% $DUOL seems to be the most hated stock in the entire market right now (excluding $HIMS). Yet the only argument I here is that it's down 80% from highs which for most investors means it must be trash. But take a look at the balance sheet. This company is dirt-cheap and won't https://t.co/PIiwzxkYA7 $DUOL seems to be the most hated stock in the entire market right now (excluding $HIMS). Yet the only argument I here is that it's down 80% from highs which for most investors means it must be trash. But take a look at the balance sheet. This company is dirt-cheap and won't"
X Link 2026-02-09T19:17Z [---] followers, [---] engagements
"$DUOL $DUOL @MMatters22596 Cool infographics what's interesting in $DUOL's case is especially its growth in terms of paid subscribers: it's booming https://t.co/MiqW0f8Zd6 @MMatters22596 Cool infographics what's interesting in $DUOL's case is especially its growth in terms of paid subscribers: it's booming https://t.co/MiqW0f8Zd6"
X Link 2026-02-09T19:19Z [---] followers, [---] engagements
"$DUOL @MMatters22596 The valuation is totally comical at this point. Anyone who still thinks this company is expensive has a poor feel for whats going on in the rest of the market and hasnt studied its financials enough @MMatters22596 The valuation is totally comical at this point. Anyone who still thinks this company is expensive has a poor feel for whats going on in the rest of the market and hasnt studied its financials enough"
X Link 2026-02-09T19:21Z [---] followers, [---] engagements
"$SOFI GBULBorrow EVP SoFiTechnologies General Counsel joins the EVP of GBUL Borrow in buying the dip at SoFi Technologies $SOFI https://t.co/DV7TCjG9Fj General Counsel joins the EVP of GBUL Borrow in buying the dip at SoFi Technologies $SOFI https://t.co/DV7TCjG9Fj"
X Link 2026-02-09T19:36Z [---] followers, [---] engagements
"$LTRX $QCOM $TER $LTRX $QCOM $TER $LTRX so much Reason with $QCOM and $TER Thermal for Drones and Robotcis https://t.co/AuZRaDuQNB $LTRX so much Reason with $QCOM and $TER Thermal for Drones and Robotcis https://t.co/AuZRaDuQNB"
X Link 2026-02-09T19:39Z [---] followers, [--] engagements
"$CRVS $CRVS Ph1b/2 SQL 400mg QD [----] $CRVS Phase2 US/Global 400mg QD $CRVS CRVS's China partner is actively testing SQL 400mg QD in a Ph1b/2 study in China w/ topline data to come likely 2H26 which could provide early support for CRVS's planned 400mg QD cohort in Ph2 US/ global studies. $CRVS CRVS's China partner is actively testing SQL 400mg QD in a Ph1b/2 study in China w/ topline data to come likely 2H26 which could provide early support for CRVS's planned 400mg QD cohort in Ph2 US/ global studies"
X Link 2026-02-09T20:04Z [---] followers, [---] engagements
"$VNDA - [---] PDUFA $vnda feb [--] PDUFA- likelyhood of advancing is high https://t.co/u116MGvCzG $vnda feb [--] PDUFA- likelyhood of advancing is high https://t.co/u116MGvCzG"
X Link 2026-02-09T21:09Z [---] followers, [---] engagements
"$VNDA [--] [--] $XBI $LLY $VNDA should be trading 4x higher. 20x when the world discovers they have the numero uno late stage drug in the world that keeps obese people on their weight loss treatments.so sad this company has shitty management with little business acumen or marketing skills🤷♂ $XBI $LLy $VNDA should be trading 4x higher. 20x when the world discovers they have the numero uno late stage drug in the world that keeps obese people on their weight loss treatments.so sad this company has shitty management with little business acumen or marketing skills🤷♂ $XBI $LLy"
X Link 2026-02-09T21:12Z [---] followers, [---] engagements
"$ETON $VNDA [--] PDUFA $ETON $VNDA $XBI Rough few days my focus will be on $ETON and $VNDA going into PDUFAs in Feb. $XBI Looking for good entries. Rough few days my focus will be on $ETON and $VNDA going into PDUFAs in Feb. $XBI Looking for good entries"
X Link 2026-02-09T21:14Z [---] followers, [---] engagements
"$CRVS $APGE $NKTR $KYMR ( ) $NKTR + $KYMR /JAKi Key Differences Inclusion/Exclusion Criteria in Atopic Dermatitis Trials $CRVS Very high-bar patients w/ prior biologic/JAKi require failed therapy refractory $APGE Allows JAKi excludes prior IL-4/IL-13 $NKTR + $KYMR exlude prior biologics/JAKi or required nave patients https://t.co/3IF66KMKGJ Key Differences Inclusion/Exclusion Criteria in Atopic Dermatitis Trials $CRVS Very high-bar patients w/ prior biologic/JAKi require failed therapy refractory $APGE Allows JAKi excludes prior IL-4/IL-13 $NKTR + $KYMR exlude prior biologics/JAKi or"
X Link 2026-02-10T08:27Z [---] followers, [---] engagements
"$AARD - Phase3 HERO [--] ToplineData [--] $BIOA $IBIO $AARD - Expands Phase [--] HERO trial to kids 7+. Toline data still on track for Q3 competitive landscape with $BIOA and $IBIO getting interesting. $AARD - Expands Phase [--] HERO trial to kids 7+. Toline data still on track for Q3 competitive landscape with $BIOA and $IBIO getting interesting"
X Link 2026-02-10T13:49Z [---] followers, [---] engagements
"$AARD ARD-101 Phase3 FDA IRB $AARD Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101 Expanding Eligibility in Phase [--] Study of Prader-Willi Syndrome https://t.co/ornKXpfW0m $AARD Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101 Expanding Eligibility in Phase [--] Study of Prader-Willi Syndrome https://t.co/ornKXpfW0m"
X Link 2026-02-10T13:53Z [---] followers, [--] engagements
"$EVMN - Evommune EVO301 Phase2a $EVMN - Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis. $EVMN - Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis"
X Link 2026-02-10T13:56Z [---] followers, [--] engagements
"$VNDA VandaPharmaceuticals HETLIOZ FDA https://pryzm.ozmosi.com/product/2117 $VNDA Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ Supplemental New Drug Application for Jet Lag Disorder More Info: https://t.co/zM6GMxghuK https://t.co/9CDllQv1ob https://pryzm.ozmosi.com/product/2117 $VNDA Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ Supplemental New Drug Application for Jet Lag Disorder More Info: https://t.co/zM6GMxghuK https://t.co/9CDllQv1ob"
X Link 2026-02-11T13:43Z [---] followers, [---] engagements
"$ASPI [---] Goldman Sachs buys [-------] shares more of $ASPI https://t.co/sbrepJtISQ Goldman Sachs buys [-------] shares more of $ASPI https://t.co/sbrepJtISQ"
X Link 2026-02-11T13:57Z [---] followers, [---] engagements
"$ASPI BNPParibasAssetManagementUK files 13G disclosing ownership of close to 1mm shares of $ASPI $ASPI BNP Paribas Asset Management UK files 13G disclosing ownership of close to 1mm shares of ASPI $ASPI BNP Paribas Asset Management UK files 13G disclosing ownership of close to 1mm shares of ASPI"
X Link 2026-02-11T14:00Z [---] followers, [---] engagements
"$ASPI BNPUK 13G$ASPI [---] $ASPI BNP Paribas Asset Management UK files 13G disclosing ownership of close to 1mm shares of ASPI $ASPI BNP Paribas Asset Management UK files 13G disclosing ownership of close to 1mm shares of ASPI"
X Link 2026-02-11T14:01Z [---] followers, [---] engagements
"$ASPI $ASPI TaronisFuels IR $ASPI I find it interesting that Michael Khorassani is also promoting ASPI for those who dont know he was doing IR for Taronis Fuels a proven industrial tech fraud. https://t.co/bhFufG56od https://t.co/nrF42YH4Jo $ASPI I find it interesting that Michael Khorassani is also promoting ASPI for those who dont know he was doing IR for Taronis Fuels a proven industrial tech fraud. https://t.co/bhFufG56od https://t.co/nrF42YH4Jo"
X Link 2026-02-11T16:28Z [---] followers, [---] engagements
"$VNDA 📉 ⚡ 7/10 : $VNDA4 💡 VNDA10.1% 👉 #Traders #Hours #Stocks https://fibalgo.com/terminal 📉 BEARISH ⚡ 7/10 After-hours healthcare small-caps volatile; VNDA drops on Q4 earnings $VNDA 💡 The news highlights significant after-hours price movements in low-market-cap healthcare stocks with VNDA declining [----] 👉 https://t.co/M6U3eWkjtJ #Traders #Hours #Stocks https://fibalgo.com/terminal 📉 BEARISH ⚡ 7/10 After-hours healthcare small-caps volatile; VNDA drops on Q4 earnings $VNDA 💡 The news highlights significant after-hours price movements in low-market-cap healthcare stocks with VNDA"
X Link 2026-02-11T21:53Z [---] followers, [---] engagements
"# # # Consolidated financial results for the fiscal year ending December Otsuka Holdings' net profit increases [---] times. Net profit and sales both reach record highs with pharmaceuticals performing well. #OtsukaPharmaceutical #Otsuka $ESPR # # # HD28 [--] https://t.co/1piRenXK3r # # # HD28 [--] https://t.co/1piRenXK3r"
X Link 2025-08-31T17:54Z [---] followers, [---] engagements
"$ANRO #ALTO-101 ALTO-101 PDE4 PDE4 cAMP ( )"
X Link 2026-01-19T20:44Z [---] followers, [---] engagements
"$ASPI $QLE $SKBL ( ) TerraPower $ASPI $ASPI $QLE $SKBL Graphic we recently put together to help better understand how these companies connect. $QLE will be interesting to see how IPO and HALEU deadlines pan out. TerraPower made it clear $ASPI was the only company who could meet their timeline and demand. https://t.co/suZSl9Ok1p $ASPI $QLE $SKBL Graphic we recently put together to help better understand how these companies connect. $QLE will be interesting to see how IPO and HALEU deadlines pan out. TerraPower made it clear $ASPI was the only company who could meet their timeline and demand."
X Link 2026-01-30T13:54Z [---] followers, [---] engagements
"$TYRA #OPPENHEIMER MatthewBiegler $TYRA AnaChart [------] 3#Pricetarget $36$50 $4.98 (16.05%) $18.98 (61.19%) Outperform #OPPENHEIMER analyst Matthew Biegler who covers $TYRA has the current 3rd biggest #pricetarget movement on AnaChart (03-Feb-2026 (10AM)) by upgrading from $36 to $50 with an increase in potential upside change from $4.98(16.05%) to $18.98(61.19%) with a rating of Outperform https://t.co/W9u958dQnd #OPPENHEIMER analyst Matthew Biegler who covers $TYRA has the current 3rd biggest #pricetarget movement on AnaChart (03-Feb-2026 (10AM)) by upgrading from $36 to $50 with an"
X Link 2026-02-05T08:30Z [---] followers, [--] engagements
"$TYRA - Phase2 🚀 ➤ -0.88% +11.33% - ➤ RVOL [----] - ➤ [-----] / 17.65% - $TYRA dosed first child in Phase 2; shares surge 🚀 ➤ +11.33% intraday after a -0.88% gap momentum confirmed ➤ RVOL [----] above-average trading interest ➤ Short Ratio [-----] / Short Float 17.65% meaningful short-squeeze risk https://t.co/RfRZyPogmU $TYRA dosed first child in Phase 2; shares surge 🚀 ➤ +11.33% intraday after a -0.88% gap momentum confirmed ➤ RVOL [----] above-average trading interest ➤ Short Ratio [-----] / Short Float 17.65% meaningful short-squeeze risk https://t.co/RfRZyPogmU"
X Link 2026-02-05T08:33Z [---] followers, [--] engagements
"$TYRA BiotechAnalyst ChrisRaymond $TYRA Layering UTUC Into Our Dabogratinib Model$TYRA Dabogratinib Biotech analyst Chris Raymond published on $TYRA "Layering UTUC Into Our Dabogratinib Model" calling out that although this is smaller opportunity TYRA can accelerate development here with the potential for this to be the first approved indication for dabogratinib. Biotech analyst Chris Raymond published on $TYRA "Layering UTUC Into Our Dabogratinib Model" calling out that although this is smaller opportunity TYRA can accelerate development here with the potential for this to be the first"
X Link 2026-02-05T08:46Z [---] followers, [--] engagements
"$ALXO Director [---] Catalist ( ) Phase2 [--] - + - ( ASPEN-09-Breast ) HER2 Phase1 [----] - ALX2004 - $XBI $IBB $ALXO Director acquires $5 million dollars at open market Catalyst: Phase [--] interim data Q3 -Evorpacept + trastuzumab - (ASPEN-09-Breast) HER2-positive metastatic breast cancer Phase [--] 1H [----] ALX2004 Solid Tumors $XBI $IBB https://t.co/m1ID3Ym3kJ $ALXO Director acquires $5 million dollars at open market Catalyst: Phase [--] interim data Q3 -Evorpacept + trastuzumab - (ASPEN-09-Breast) HER2-positive metastatic breast cancer Phase [--] 1H [----] ALX2004 Solid Tumors $XBI $IBB"
X Link 2026-02-05T09:56Z [---] followers, [---] engagements
"$TYRA - Jefferies TyraBiosciences ( PT ) $32$43 : $TYL -Needham reiterates Tyler Technologies $750 target Buy -DA Davidson maintains $510 target Neutral - $TYRA -Jefferies raises Tyra Biosciences target to $43 from $32 Buy - $UAL -Citi adds United Airlines to upside [--] day catalyst watch Raises target to $155 from $153 Buy - $TYL -Needham reiterates Tyler Technologies $750 target Buy -DA Davidson maintains $510 target Neutral - $TYRA -Jefferies raises Tyra Biosciences target to $43 from $32 Buy - $UAL -Citi adds United Airlines to upside [--] day catalyst watch Raises target to $155 from"
X Link 2026-02-08T15:45Z [---] followers, [--] engagements
"$BFRI [---] Q4 [----] $BFRI looking juicy here. Trading just below 1x sales with multiple approvals next [--] months and breakeven this year. Beat q4 estimates and I suspect they hit closer to 50mm this year then its off to the races $BFRI looking juicy here. Trading just below 1x sales with multiple approvals next [--] months and breakeven this year. Beat q4 estimates and I suspect they hit closer to 50mm this year then its off to the races"
X Link 2026-02-09T12:20Z [---] followers, [---] engagements
"$ETON $KYTX $ETON 2/25 PDUFA $KYTX Phase2 BLA2026 Phase2 Catalist @BiotechAutist @asamimes @BrianSkorney @LeerinkPartners @ClearStreetNews Well $ETON has PDUFA on2/25. $KYTX has a nr of potential catalysts with readings (Ph2 stiff person syndrome BLA filling interim Ph2 myasthenia gravis extended in 2026) @BiotechAutist @asamimes @BrianSkorney @LeerinkPartners @ClearStreetNews Well $ETON has PDUFA on2/25. $KYTX has a nr of potential catalysts with readings (Ph2 stiff person syndrome BLA filling interim Ph2 myasthenia gravis extended in 2026)"
X Link 2026-02-09T14:42Z [---] followers, [---] engagements
"$XBI / $ARDX $DAWN $SLNO $TMDX $HROW #ARDX #DAWN #SLNO #TMDX #HROW #XBI $XBI few small cap biotech companies that still seems undervalued with approved drug (s) on the market. De-risked as earnings and drug launches have done better than before $ARDX $DAWN $SLNO $TMDX $HROW $XBI few small cap biotech companies that still seems undervalued with approved drug (s) on the market. De-risked as earnings and drug launches have done better than before $ARDX $DAWN $SLNO $TMDX $HROW"
X Link 2026-02-09T16:14Z [---] followers, [--] engagements
"$NUVB NuvationBio IDH1 Safusidenib Phase3 SIGMA G203 https://pryzm.ozmosi.com/product/22745 $NUVB Nuvation Bio Announces Pivotal Global Phase [--] SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma More Info: https://t.co/ybrR3GaTOQ https://t.co/4ABtiXo1GM https://pryzm.ozmosi.com/product/22745 $NUVB Nuvation Bio Announces Pivotal Global Phase [--] SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma More Info: https://t.co/ybrR3GaTOQ https://t.co/4ABtiXo1GM"
X Link 2026-02-09T19:10Z [---] followers, [---] engagements
"$NUVB IDH1 ( Safusidenib ) Phase3 G203 $NUVB Announces Pivotal Global Phase [--] SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma https://t.co/Xk3LO2x2ix $NUVB Announces Pivotal Global Phase [--] SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma https://t.co/Xk3LO2x2ix"
X Link 2026-02-09T19:31Z [---] followers, [---] engagements
"$VRTX $VNDA Vertex [----] Jounravx [---] $VRTX $VNDA Vertex plans to triple Jounravx patients to [---] million in [----] while expanding into pain and renal disease franchises $VRTX $VNDA Vertex plans to triple Jounravx patients to [---] million in [----] while expanding into pain and renal disease franchises"
X Link 2026-02-11T13:53Z [---] followers, [---] engagements
"$VRTX JOURNAVXsuzetrigine [--] NaV1.8"
X Link 2026-02-11T13:54Z [---] followers, [--] engagements
"$GELS Gelteq HealthyExtracts $GELS Gelteq and Healthy Extracts to Expand Gel-Based Nutrition Technologies with New Strategic Manufacturing & Commercial Partnership https://t.co/a6wM5mOovm $GELS Gelteq and Healthy Extracts to Expand Gel-Based Nutrition Technologies with New Strategic Manufacturing & Commercial Partnership https://t.co/a6wM5mOovm"
X Link 2026-02-11T21:20Z [---] followers, [--] engagements
"$VNDA Vanda VQW-765 YE26 Phase3 Phobia Social $VNDA Vanda announced they will present P3 Phobia Social results in YE26 for VQW-765 More Info: https://t.co/YkHjDciIlR https://t.co/Y3A6l8KLcf $VNDA Vanda announced they will present P3 Phobia Social results in YE26 for VQW-765 More Info: https://t.co/YkHjDciIlR https://t.co/Y3A6l8KLcf"
X Link 2026-02-12T20:29Z [---] followers, [--] engagements
"$VNDA Vanda Milsaperidone Phase3 YE26 $VNDA Vanda announced they will present P3 Depressive Disorder Major results in YE26 for Milsaperidone More Info: https://t.co/5cBb1LRf5w https://t.co/nH2ssEtTAW $VNDA Vanda announced they will present P3 Depressive Disorder Major results in YE26 for Milsaperidone More Info: https://t.co/5cBb1LRf5w https://t.co/nH2ssEtTAW"
X Link 2026-02-12T20:32Z [---] followers, [---] engagements
"$NKTR Rezpegaldesleukin Rezpeg NektarTherapeutics T RegulatoryTcell : Treg IL-2 ( )"
X Link 2026-02-12T21:46Z [---] followers, [---] engagements
"$NKTR ( ) IL-13 Rezpeg First-in-class Treg"
X Link 2026-02-12T21:47Z [---] followers, [---] engagements
"$OGN Organon 2025Q4 📊 ❌ EPS: $0.63 : 30.00% (from $0.90) ❌ : $1.507B : 5.34% (from $1.592B) 📊 Organon $OGN Q4 [----] Earnings ❌ Earnings Miss Adj. EPS: $0.63 YoY: 30.00% (from $0.90) ❌ Revenue Miss Sales: $1.507B YoY: 5.34% (from $1.592B) 📊 Organon $OGN Q4 [----] Earnings ❌ Earnings Miss Adj. EPS: $0.63 YoY: 30.00% (from $0.90) ❌ Revenue Miss Sales: $1.507B YoY: 5.34% (from $1.592B)"
X Link 2026-02-13T04:29Z [---] followers, [--] engagements
"$OGN [------] Nexplanon 7% $OGN - [----] revenue hits $6.2B Launched new biosimilars and chopped debt. Nexplanon patents expire soon though and that's a big chunk of revenue. Down 7% today. $OGN - [----] revenue hits $6.2B Launched new biosimilars and chopped debt. Nexplanon patents expire soon though and that's a big chunk of revenue. Down 7% today"
X Link 2026-02-13T04:33Z [---] followers, [--] engagements
"$ASPI $ASPI [---] BlackRock buys [----] millions shares more of $ASPI https://t.co/5Tkywq81yN BlackRock buys [----] millions shares more of $ASPI https://t.co/5Tkywq81yN"
X Link 2026-02-13T13:26Z [---] followers, [----] engagements
"$OCUL $OCUL AXPAXLI AMD SOL-1 Phase3 [-----] [--] $OCUL topline results of the SOL-1 Phase [--] superiority clinical trial of AXPAXLI for the treatment of wet AMD are expected to be presented at the 49th Macula Society Annual Meeting taking place between Feb 25th 28th $OCUL topline results of the SOL-1 Phase [--] superiority clinical trial of AXPAXLI for the treatment of wet AMD are expected to be presented at the 49th Macula Society Annual Meeting taking place between Feb 25th 28th"
X Link 2026-02-13T14:28Z [---] followers, [---] engagements
"#Iran #Uranium #HEU 400HEU Iran official says Tehran considering handing over [---] kg of highly enriched uranium (HEU) accepting zero enrichment under a consortium arrangement as a solution in a deal that should also include lifting economic sanctions https://t.co/ESN8OQiS9s Iran official says Tehran considering handing over [---] kg of highly enriched uranium (HEU) accepting zero enrichment under a consortium arrangement as a solution in a deal that should also include lifting economic sanctions https://t.co/ESN8OQiS9s"
X Link 2026-02-13T21:18Z [---] followers, [---] engagements
"$KYMR $CRVS $APGE Phase2b AD ( ) Different Ph2b AD trial designs orals may take less time than injectables and close gap w/ injectable programs further ahead oral $KYMR KT-621 [--] wks [--] wk open label extension $CRVS #soquelitinib [--] wks 30-day follow-up inj $APGE $NKTR 16wk data [--] wk maintenance https://t.co/EocGY0UPie Different Ph2b AD trial designs orals may take less time than injectables and close gap w/ injectable programs further ahead oral $KYMR KT-621 [--] wks [--] wk open label extension $CRVS #soquelitinib [--] wks 30-day follow-up inj $APGE $NKTR 16wk data [--] wk maintenance"
X Link 2026-02-13T21:26Z [---] followers, [---] engagements
"$KYMR $CRVS $APGE $NKTR ( ) - $KYMR KT-6211652 $CRVS #1230 - $APGE $NKTR [----] Different Ph2b AD trial designs orals may take less time than injectables and close gap w/ injectable programs further ahead oral $KYMR KT-621 [--] wks [--] wk open label extension $CRVS #soquelitinib [--] wks 30-day follow-up inj $APGE $NKTR 16wk data [--] wk maintenance https://t.co/EocGY0UPie Different Ph2b AD trial designs orals may take less time than injectables and close gap w/ injectable programs further ahead oral $KYMR KT-621 [--] wks [--] wk open label extension $CRVS #soquelitinib [--] wks 30-day follow-up inj $APGE"
X Link 2026-02-13T21:27Z [---] followers, [---] engagements
"$CRVS ITK #Soquelitinib AD 🔹 🔹 EASI-75 🔹 $NKTR $KYMR $EVMN $CRVS Mizuho discusses oral ITK inhibitor #soquelitinib recent AD data: 🔹 "Data were VERY excellent in terms of efficacy and also in terms of safety" 🔹 "Best-in-Class EASI-75 almost Best-in-Disease type of efficacy" 🔹 "intriguing signals that you can get durative efficacy" https://t.co/6WkozViVTB $CRVS Mizuho discusses oral ITK inhibitor #soquelitinib recent AD data: 🔹 "Data were VERY excellent in terms of efficacy and also in terms of safety" 🔹 "Best-in-Class EASI-75 almost Best-in-Disease type of efficacy" 🔹 "intriguing"
X Link 2026-02-13T21:34Z [---] followers, [---] engagements
"@Biotech2k1 No. I'm "JAPANESE ""
X Link 2025-08-01T20:58Z [---] followers, [----] engagements
"$QNCX JMPQuince Therapeutics $QNCX coverageOutperform [--] [----] $XBI $SRPT $VRTX Citizens JMP initiated coverage of Quince Therapeutics $QNCX with an Outperform rating and $9 PT Current price: $1.69 $XBI $SRPT $VRTX Citizens JMP initiated coverage of Quince Therapeutics $QNCX with an Outperform rating and $9 PT Current price: $1.69 $XBI $SRPT $VRTX"
X Link 2025-08-05T13:47Z [---] followers, [---] engagements
"$QNCX The Lancet Neurology $QNCX Phase3 Phase3 6-9 $XBI $ABVX $SRPT This is what I mean see $QNCX prior Ph3 data published by The Lancet Neurology Look at current Ph3 trial primary population (6-9y) numbers off the charts $XBI $ABVX $SRPT https://t.co/eU1iTpNrOz This is what I mean see $QNCX prior Ph3 data published by The Lancet Neurology Look at current Ph3 trial primary population (6-9y) numbers off the charts $XBI $ABVX $SRPT https://t.co/eU1iTpNrOz"
X Link 2025-08-05T13:54Z [---] followers, [---] engagements
"$ARVN Logos $SLRN $KROS =5 $ARVN Logos joining the special distribution-gang. One of those ugly registers with a large block of passive capital which will vote for every dumb thing management puts out (see SLRN KROS). Only am short Puts (Strike=5). Might put something more aggressive on. https://t.co/64Qf5o8IHe $ARVN Logos joining the special distribution-gang. One of those ugly registers with a large block of passive capital which will vote for every dumb thing management puts out (see SLRN KROS). Only am short Puts (Strike=5). Might put something more aggressive on. https://t.co/64Qf5o8IHe"
X Link 2025-08-07T15:23Z [---] followers, [---] engagements
"$NRXP NRx Pharmaceuticals Inc.NASDAQ: $NRXP NRX-100 FDA - #PharmaNews #Mentalillness #Mentalhealth #mentalhealthmatters #Ketamin https://ir.nrxpharma.com/news-releases/news-release-details/nrx-pharmaceuticals-inc-nasdaqnrxp-granted-fda-fast-track NRx Pharmaceuticals Inc. (NASDAQ: $NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression including Bipolar Depression Read More - https://t.co/ifD2YPCCCJ #PharmaNews #mentalillness #mentalhealth #mentalhealthmatters #ketamine"
X Link 2025-08-11T21:36Z [---] followers, [---] engagements
"$HUMA Humacyte Inc. Symvess"
X Link 2025-08-14T15:31Z [---] followers, [---] engagements
"$QURE AAV AMT-130 $PTCT $WVE $NBIX $IONS - $RHHBY $TEVA $KRRO $HLUBF $HLBBF Mizuho $QURE to OP-$30 from N-$20. $PTCT $WVE $NBIX $IONS - $RHHBY $TEVA $KRRO $HLUBF $HLBBF Mizuho: We upgrade $QURE from Neutral to Outperform and increase our PT from $20 to $30 as (1) we believe AMT-130 could be a dominant player in the evolving Huntington's disease (HD) Mizuho $QURE to OP-$30 from N-$20. $PTCT $WVE $NBIX $IONS - $RHHBY $TEVA $KRRO $HLUBF $HLBBF Mizuho: We upgrade $QURE from Neutral to Outperform and increase our PT from $20 to $30 as (1) we believe AMT-130 could be a dominant player in the"
X Link 2025-08-14T16:40Z [---] followers, [---] engagements
"$LXRX $NVO [--] LX9851 [---] 🚀 🚨 $LXRX Lexicon Pharmaceuticals can be a game changer in the weight-loss drug marketafter revealing a $1 billion deal with the leading company $NVO Novo Nordisk on drug LX9851. Besides the high 5% borrow fee and 15% short volume are ideal for a potential short squeeze🚀 https://t.co/PpJvDLskpN 🚨 $LXRX Lexicon Pharmaceuticals can be a game changer in the weight-loss drug marketafter revealing a $1 billion deal with the leading company $NVO Novo Nordisk on drug LX9851. Besides the high 5% borrow fee and 15% short volume are ideal for a potential short squeeze🚀"
X Link 2025-08-18T16:50Z [---] followers, [---] engagements
"$LXRX Genome5000 [---] Finally getting some recognition $LXRX . focused on developing innovative medicines through its Genome5000 program which has identified over [---] protein targets with therapeutic potential https://t.co/3zYFUw4okb Finally getting some recognition $LXRX . focused on developing innovative medicines through its Genome5000 program which has identified over [---] protein targets with therapeutic potential https://t.co/3zYFUw4okb"
X Link 2025-08-18T16:52Z [---] followers, [---] engagements
"$TNXP FDATONMYA FDA Approves TONMYA (cyclobenzaprine sublingual tablet) for Fibromyalgia https://t.co/OmaKGUfCCZ FDA Approves TONMYA (cyclobenzaprine sublingual tablet) for Fibromyalgia https://t.co/OmaKGUfCCZ"
X Link 2025-08-19T14:21Z [---] followers, [---] engagements
"$UNCY 815FDA [--] @colemana64 Yes that may be the point of these bogus lawsuits to bring down the price. In most cases the short is behind. But honestly today's price decline may be directly attributable to 15Aug financing. It will quickly come back up in anticipation of FDA Type [--] Meeting feedback any day @colemana64 Yes that may be the point of these bogus lawsuits to bring down the price. In most cases the short is behind. But honestly today's price decline may be directly attributable to 15Aug financing. It will quickly come back up in anticipation of FDA Type [--] Meeting feedback any day"
X Link 2025-08-20T14:01Z [---] followers, [---] engagements
"$ARDX $ARDX 2025162024119% 📍637 📍202589 📍2025 $ARDX Kyowa Kirin who license the tenapanor drug from $ARDX announced a 119% increase in sales for the Jan-Jun [----] period compared to [----]. 📍In first [--] months they did [---] Bill in sales. 📍Their target for FY25 is [---] Bill. 📍That means they're expecting a strong 2h'25. https://t.co/mtplRwxCyU $ARDX Kyowa Kirin who license the tenapanor drug from $ARDX announced a 119% increase in sales for the Jan-Jun [----] period compared to [----]. 📍In first [--] months they did [---] Bill in sales. 📍Their target for FY25 is [---] Bill. 📍That means they're"
X Link 2025-08-20T17:05Z [---] followers, [---] engagements
"Upcoming Catalysts for Next Week Aug [--] 2025: $OSTX $OTLK Aug [--] 2025: $SNY $NVS $COYA Aug [--] 2025: $CYTK $RPRX $RHHBY $ALNY"
X Link 2025-08-22T21:12Z [---] followers, [---] engagements
"$NTLA $CRSP $BEAM $PRME [--] Turns out I slept on Paul Grahams bullish gene-editing prophecy from last Feb. Here it is in case you missed it too I think he knows a thing or two. $NTLA $CRSP $BEAM $PRME Turns out I slept on Paul Grahams bullish gene-editing prophecy from last Feb. Here it is in case you missed it too I think he knows a thing or two. $NTLA $CRSP $BEAM $PRME"
X Link 2025-08-23T06:24Z [---] followers, [---] engagements
"@teradasyacho 10"
X Link 2025-08-24T13:29Z [---] followers, [----] engagements
"$ENPH Enphase [----] TPO IQ8HC $ENPH SECURES $50M SOLAR FINANCING DEAL UP 11% IN [--] WEEK Bullish vibes are building for solar if tax credits stick and financing costs ease. A drop in rates on residential loans could fuel another leg higher for the sector. Enphase signed a safe harbor agreement with a solar https://t.co/JPZWzx2nXE $ENPH SECURES $50M SOLAR FINANCING DEAL UP 11% IN [--] WEEK Bullish vibes are building for solar if tax credits stick and financing costs ease. A drop in rates on residential loans could fuel another leg higher for the sector. Enphase signed a safe harbor agreement with a"
X Link 2025-08-24T14:22Z [---] followers, [--] engagements
"Yamaha Motor Co. Ltd. [----] World's No. [--] in Motorcycles World's No. [--] in Outboard Motors and Personal Watercraft PER: 23x PBR: 0.9x Forecast Dividend Yield: 4.6% Forecast Dividend Payout: 108% Financial Results☁ Forecast EPS: [--] Dividend: [--] [----] [--] [--] PER23 PBR0.9 4.6% 108% ☁ EPS4650 https://t.co/zCaN5J3Zzc [----] [--] [--] PER23 PBR0.9 4.6% 108% ☁ EPS4650 https://t.co/zCaN5J3Zzc"
X Link 2025-08-24T16:30Z [---] followers, [---] engagements
"$CAPR $REPL $CAPR $REPL CRL AdComms Prasad FDA FDA Vinay CBER RCT 2/ In both $CAPR and $REPL CRLs (both w/o AdComms) Prasad (and other senior FDA leaders) overruled FDA reviewers. This was a behavior Vinay criticized previous CBER head for. These decisions support his critics' labelling of him only accepting RCTs. https://t.co/plY5oSPOvs 2/ In both $CAPR and $REPL CRLs (both w/o AdComms) Prasad (and other senior FDA leaders) overruled FDA reviewers. This was a behavior Vinay criticized previous CBER head for. These decisions support his critics' labelling of him only accepting RCTs."
X Link 2025-08-25T15:57Z [---] followers, [---] engagements
"$SNYR : $9.1M (+33% YoY) 77.8% (72.1%) : $1.2M (+58% YoY) $HCWB $OSRH $OPAD $CAPS $STSS $AEHR $CGTX $SUPX $HIT $TWOH $DTREF $AIBT 🚀 $SNYR: Major Distribution Breakthrough & Profit Surge Revenue: $9.1M (+33% YoY). Gross Margin Hit 77.8% (up from 72.1% YoY) industry-leading profitability. Net Income: $1.2M (+58% YoY). $HCWB $OSRH $OPAD $CAPS $STSS $AEHR $CGTX $SUPX $HIT $TWOH $DTREF $AIBT 🚀 $SNYR: Major Distribution Breakthrough & Profit Surge Revenue: $9.1M (+33% YoY). Gross Margin Hit 77.8% (up from 72.1% YoY) industry-leading profitability. Net Income: $1.2M (+58% YoY). $HCWB $OSRH $OPAD"
X Link 2025-08-25T20:38Z [---] followers, [----] engagements
"$ABCL [--]. T (TCEs) $ABCL T : PSMACD3 - - [--]. Safer T-cell engagers (TCEs) $ABCL designs cancer-fighting T-cells that minimize dangerous immune overreactions. Ex: PSMACD3 for prostate cancer targets tumors while sparing healthy tissue. Safer drugs - easier approvals - more partnerships. https://t.co/iwTHoVhWj8 [--]. Safer T-cell engagers (TCEs) $ABCL designs cancer-fighting T-cells that minimize dangerous immune overreactions. Ex: PSMACD3 for prostate cancer targets tumors while sparing healthy tissue. Safer drugs - easier approvals - more partnerships. https://t.co/iwTHoVhWj8"
X Link 2025-08-26T13:52Z [---] followers, [---] engagements
"$ARDX AI Ardelyx 3-0 $ARDX AI predicts with confidence Ardelyx wins as witnessed by unanimous vote 3-0. We are so back. https://t.co/JSchIPPC1p $ARDX AI predicts with confidence Ardelyx wins as witnessed by unanimous vote 3-0. We are so back. https://t.co/JSchIPPC1p"
X Link 2025-08-26T14:05Z [---] followers, [---] engagements
"$ABCL AbCellera ABCL575 Phase1 +2.03% $ABCL +2.03% today as AbCellera Doses First Participants in a Phase [--] Clinical Trial of ABCL575 More Info: https://t.co/8VcQirUjbP https://t.co/Q992USj9mE $ABCL +2.03% today as AbCellera Doses First Participants in a Phase [--] Clinical Trial of ABCL575 More Info: https://t.co/8VcQirUjbP https://t.co/Q992USj9mE"
X Link 2025-08-27T15:01Z [---] followers, [---] engagements
"$ESPR 🍿 @MACROVET888 $ESPR Could be. Stage is set for major success this surely would be the time to try to steal the company before the price starts to really rise🍿 https://t.co/hLeqJQiqQZ @MACROVET888 $ESPR Could be. Stage is set for major success this surely would be the time to try to steal the company before the price starts to really rise🍿 https://t.co/hLeqJQiqQZ"
X Link 2025-08-31T16:38Z [---] followers, [---] engagements
"$ESPR $ESPR Ignore the biotech games. Payday is coming https://t.co/HD2Ylcyk2F $ESPR Ignore the biotech games. Payday is coming https://t.co/HD2Ylcyk2F"
X Link 2025-08-31T16:54Z [---] followers, [---] engagements
"# #OtsukaPharmaceutical $ESPR 2025829"
X Link 2025-08-31T17:07Z [---] followers, [---] engagements
"#OtsukaPharmaceutical $ESPR [--] ( )"
X Link 2025-08-31T17:10Z [---] followers, [---] engagements
"$HUMA $SENS http://patreon.com/Whatmarketmind http://patreon.com/Whatmarketmind"
X Link 2025-09-02T14:18Z [---] followers, [---] engagements
"$SGMO $QURE $SGMO One more thought: $SGMO has repeatedly messaged that partners have interestbut worry about regulatory risk. With the FDA easing and $QURE clearly being YEARS from something close after basically needing to start over at lower dose (imo only based on SAEs in small sample) I think One more thought: $SGMO has repeatedly messaged that partners have interestbut worry about regulatory risk. With the FDA easing and $QURE clearly being YEARS from something close after basically needing to start over at lower dose (imo only based on SAEs in small sample) I think"
X Link 2025-09-05T17:29Z [---] followers, [---] engagements
"$SGMO $QURE FDA $QURE SAE DD One more thought: $SGMO has repeatedly messaged that partners have interestbut worry about regulatory risk. With the FDA easing and $QURE clearly being YEARS from something close after basically needing to start over at lower dose (imo only based on SAEs in small sample) I think One more thought: $SGMO has repeatedly messaged that partners have interestbut worry about regulatory risk. With the FDA easing and $QURE clearly being YEARS from something close after basically needing to start over at lower dose (imo only based on SAEs in small sample) I think"
X Link 2025-09-05T17:30Z [---] followers, [----] engagements
"#SPX #SP500 SP500 $ENPH ( Enphase Energy ) $CZR ( Caesars Entertainment ) $MKTX (Marketaxess Holdings ) SP00 $HOOD ( Robinhood Markets ) $APP ( Applovin Corp ) $EME ( EMCOR Group Inc )"
X Link 2025-09-10T14:35Z [---] followers, [---] engagements
"$GLSI 📈 / Greenwich Lifesciences Inc 🕒 7:00 💥 +15.73% 🔍 Greenwich LifeSciences ( $GLSI ) GLSI-100 FDA 📈FOLLOW-UP /Impact after news alert Greenwich Lifesciences Inc $GLSI 🕒Time of detection: 7:00 AM (UTC-4) New York 💥Move: +15.73% 🔍News: Greenwich LifeSciences' GLSI-100 Granted US FDA Fast Track Designation ⚡ Follow us for real-time scalping alerts 📊Chart #Scalping https://t.co/vO1BMmJcuO 📈FOLLOW-UP /Impact after news alert Greenwich Lifesciences Inc $GLSI 🕒Time of detection: 7:00 AM (UTC-4) New York 💥Move: +15.73% 🔍News: Greenwich LifeSciences' GLSI-100 Granted US FDA Fast"
X Link 2025-09-10T20:42Z [---] followers, [---] engagements
"$RNA $TRML DM1 FSHD ( ) $RNA Novartis strikes again After walking away from $cytk deal early '24 they may have done so again with Avidity. $trml yesterday may have been the tell. In any case before DM1 and FSHD pivotals reading out this was an impossible deal to close now. $RNA Novartis strikes again After walking away from $cytk deal early '24 they may have done so again with Avidity. $trml yesterday may have been the tell. In any case before DM1 and FSHD pivotals reading out this was an impossible deal to close now"
X Link 2025-09-10T21:16Z [---] followers, [---] engagements
"$VERA Vera TherapeuticsIgAORIGIN346% $XBI $IBB $XPH $PPH https://pryzm.ozmosi.com/product/2843 $VERA Vera Therapeutics reports 46% decrease in proteinuria with Atacicept in ORIGIN Phase [--] study for adults with IgA nephropathy. More Info: https://t.co/GsNbxwNYuG $XBI $IBB $XPH $PPH https://t.co/PWapTmP6Oz https://pryzm.ozmosi.com/product/2843 $VERA Vera Therapeutics reports 46% decrease in proteinuria with Atacicept in ORIGIN Phase [--] study for adults with IgA nephropathy. More Info: https://t.co/GsNbxwNYuG $XBI $IBB $XPH $PPH https://t.co/PWapTmP6Oz"
X Link 2025-09-15T02:36Z [---] followers, [---] engagements
"$ARQT Arcutis Biotherapeutics Inc. $ARQT Arcutis Biotherapeutics Inc. Data insight $ARQT: Computational framework detects fading impulse immediate dynamics + fundamental headwinds strategic positioning. Defensive strategies strongly favored over aggressive. $ARQT Arcutis Biotherapeutics Inc. Data insight $ARQT: Computational framework detects fading impulse immediate dynamics + fundamental headwinds strategic positioning. Defensive strategies strongly favored over aggressive"
X Link 2025-10-15T14:22Z [---] followers, [---] engagements
"( ) $GEN +5 $CSCO +5 $FFIV +11 ( ) Cybersecurity Is Quietly Becoming the Most Powerful Growth Story in Tech The global cybersecurity market is now estimated between $225B$300B for [--------] making it one of the largest and fastest-growing segments in all of technology. According to Gartner end-user security https://t.co/rSfWUAcJZo Cybersecurity Is Quietly Becoming the Most Powerful Growth Story in Tech The global cybersecurity market is now estimated between $225B$300B for [--------] making it one of the largest and fastest-growing segments in all of technology. According to Gartner end-user"
X Link 2025-10-16T16:02Z [---] followers, [---] engagements
"$CLLN Clene Inc CNM-Au8"
X Link 2025-10-28T19:05Z [---] followers, [---] engagements
"$NRSN ALS PrimeC Phase3 FDA NeuroSense Receives FDA Clearance to Initiate Pivotal Phase [--] Trial for PrimeC in ALS $NRSN https://t.co/IlKLl5JfXd NeuroSense Receives FDA Clearance to Initiate Pivotal Phase [--] Trial for PrimeC in ALS $NRSN https://t.co/IlKLl5JfXd"
X Link 2025-11-24T21:58Z [---] followers, [---] engagements
"$PLX $ION $GERN - $PLX $IOVA $GERN- Appreciated David sharing a few of his options income trades to finish out the year Love it when ppl make my framework their own/ incorporate into their system & strategy https://t.co/e7z43BPaRu $PLX $IOVA $GERN- Appreciated David sharing a few of his options income trades to finish out the year Love it when ppl make my framework their own/ incorporate into their system & strategy https://t.co/e7z43BPaRu"
X Link 2025-12-24T14:23Z [---] followers, [---] engagements
"SNDX $KURA / $NUVB $NUVL :) KMT2A 2026-2028 + NPM1 + $SNDX $KURA $NUVB $NUVL @Andre_AGTC @develiforever it will :) Maintenance setting for KMT2A kicking in 2026-2028 + NPM1 +off label combos earlier line $SNDX $KURA Re $NUVB doubt you will see $NUVL catch up in frontline for quite a few years But again opinions are what make markets Hope [----] is your best year yet my friend @Andre_AGTC @develiforever it will :) Maintenance setting for KMT2A kicking in 2026-2028 + NPM1 +off label combos earlier line $SNDX $KURA Re $NUVB doubt you will see $NUVL catch up in frontline for quite a few years But"
X Link 2026-01-02T15:18Z [---] followers, [---] engagements
"$RGNX Regenxbio [------] Clemidsogenelanparvovec Phase3 II https://pryzm.ozmosi.com/product/25156 $RGNX Regenxbio presented Phase [--] Mucopolysaccharidosis II results on 2025-09-05 for Clemidsogene lanparvovec More Info: https://t.co/8yqji8GXR3 https://t.co/wyuyE6gYJ8 https://pryzm.ozmosi.com/product/25156 $RGNX Regenxbio presented Phase [--] Mucopolysaccharidosis II results on 2025-09-05 for Clemidsogene lanparvovec More Info: https://t.co/8yqji8GXR3 https://t.co/wyuyE6gYJ8"
X Link 2026-01-02T21:13Z [---] followers, [---] engagements
"$RGNX @REGENXBIO Prospects for @REGENXBIO's clemidsogene lanparvovec approval in Hunter syndrome https://t.co/d6TzXxOP0p Prospects for @REGENXBIO's clemidsogene lanparvovec approval in Hunter syndrome https://t.co/d6TzXxOP0p"
X Link 2026-01-02T21:16Z [---] followers, [---] engagements
"$XFOR $XFOR $4.23$4.50 $5 $XFOR: XFOR defended $4.23; reclaim $4.50 and youre back in trend-rebuild mode. Options lens: $5 is the key strike to watch if momentum flips. $XFOR: XFOR defended $4.23; reclaim $4.50 and youre back in trend-rebuild mode. Options lens: $5 is the key strike to watch if momentum flips"
X Link 2026-01-07T20:36Z [---] followers, [--] engagements
"$AQST - FDA NDA $AQST $SPRY CRL [--] ( ) $AQST - The company said that the FDA has found deficiencies in the NDA. AQST did not list any specifics. This is the advantage of having the Fast Track designation. I believe it will be worked out. Remember what happened to $SPRY even with CRL the price recovered within [--] $AQST - The company said that the FDA has found deficiencies in the NDA. AQST did not list any specifics. This is the advantage of having the Fast Track designation. I believe it will be worked out. Remember what happened to $SPRY even with CRL the price recovered within 4"
X Link 2026-01-09T14:34Z [---] followers, [---] engagements
"1/9 ( ) $MPLT 3% $CATX 2% 212Pb VMT--NET $INKT 2% AgenT-797 [--] 📌 Biotech Stock News 1/9 @ Open $CGON 21% Updated Timeline for PIVOT-006 Data $PDSB 15% FDA Alignment on PFS as Endpoint $IBIO 14% $26M Private Placement $QURE 14% Type A Meeting Scheduled with FDA $KRYS 5% Positive Interim Clinical Update on KB407 $MPLT 3% Topline Results https://t.co/Dktelv9F3X 📌 Biotech Stock News 1/9 @ Open $CGON 21% Updated Timeline for PIVOT-006 Data $PDSB 15% FDA Alignment on PFS as Endpoint $IBIO 14% $26M Private Placement $QURE 14% Type A Meeting Scheduled with FDA $KRYS 5% Positive Interim Clinical"
X Link 2026-01-09T17:14Z [---] followers, [---] engagements
"$GLUE 50% 📈 MGD MRT-8102 hsCRP 94% hsCRP [--] mg/L (1 Phase [--] 👇 https://offers.bpiq.com/big-mover-lpmo=jun $GLUE up 50% 📈 Oral MGD MRT-8102 shows rapid hsCRP reduction 94% of patients suppressed to [--] mg/L hsCRP Biologic-like efficacy with no SAEs reported (Phase 1) Dont miss out on future Big Movers Access our FREE Big Mover Report 👇 https://t.co/g8sMZ9xwJM https://offers.bpiq.com/big-mover-lpmo=jun $GLUE up 50% 📈 Oral MGD MRT-8102 shows rapid hsCRP reduction 94% of patients suppressed to [--] mg/L hsCRP Biologic-like efficacy with no SAEs reported (Phase 1) Dont miss out on future Big"
X Link 2026-01-12T22:00Z [---] followers, [---] engagements
"$RGNX PDUFA : ( [------] ) / RGX-121 / RGX-121 MPS II CNS AAV9 ( ) $RGNX (February [--] 2026) RGX-121 / Hunter syndrome / PDUFA Why RGX-121 is different One-time CNS AAV9 gene therapy targeting the genetic cause of neuronopathic MPS II. Pivotal CAMPSIITE signal Primary endpoint met; CSF HS D2S6 82% through 1Y (80% maintained) https://t.co/BJZtSHngUH $RGNX (February [--] 2026) RGX-121 / Hunter syndrome / PDUFA Why RGX-121 is different One-time CNS AAV9 gene therapy targeting the genetic cause of neuronopathic MPS II. Pivotal CAMPSIITE signal Primary endpoint met; CSF HS D2S6 82% through 1Y (80%"
X Link 2026-01-14T12:48Z [---] followers, [---] engagements
"$RGNX PDUFA : ( [------] ) / RGX-121 / CAMPSIITE HS D2S6 182%80% [--] BSID-III [--] HS D2S6 1r [-----] $RGNX (February [--] 2026) RGX-121 / Hunter syndrome / PDUFA Why RGX-121 is different One-time CNS AAV9 gene therapy targeting the genetic cause of neuronopathic MPS II. Pivotal CAMPSIITE signal Primary endpoint met; CSF HS D2S6 82% through 1Y (80% maintained) https://t.co/BJZtSHngUH $RGNX (February [--] 2026) RGX-121 / Hunter syndrome / PDUFA Why RGX-121 is different One-time CNS AAV9 gene therapy targeting the genetic cause of neuronopathic MPS II. Pivotal CAMPSIITE signal Primary endpoint met; CSF HS"
X Link 2026-01-14T12:49Z [---] followers, [---] engagements
"$AMIX $TOON $SOAR $SJ $BNRG $PNPNF $PRSO [--] [-----] #ShortSqueeze #TechStocks #Momentum #BreakoutStocks #StocksToWatch #SmallCaps #WallStreetToBayStreet https://thestreetreports.com/stocks-under-1-amix-toon-soar-sj-bnrg-pnpnf-prso-double-digit-2026-watchlist/ Stocks Under $1: $AMIX $TOON $SOAR $SJ $BNRG $PNPNF $PRSO Double-Digit [----] Watchlist https://t.co/7j44LAakYg #ShortSqueeze #TechStocks #Momentum #BreakoutStocks #StocksToWatch #SmallCaps #WallStreetToBayStreet https://thestreetreports.com/stocks-under-1-amix-toon-soar-sj-bnrg-pnpnf-prso-double-digit-2026-watchlist/ Stocks Under $1: $AMIX"
X Link 2026-01-14T15:34Z [---] followers, [---] engagements
"$CMMB $CMMB VWAP $CMMB needs to break this general downtrend. Keeping it on watch for potential reversal and VWAP test. https://t.co/w75dzHy5LM $CMMB needs to break this general downtrend. Keeping it on watch for potential reversal and VWAP test. https://t.co/w75dzHy5LM"
X Link 2026-01-16T16:47Z [---] followers, [--] engagements
"$ANRO #ALTO-100 ALTO-100 ( )"
X Link 2026-01-19T20:36Z [---] followers, [--] engagements
"$ANRO #ALTO-100 ( ) ALTO-100 PhaseIIb"
X Link 2026-01-19T20:39Z [---] followers, [--] engagements
"$ANRO #ALTO-101 ( ) Phase2 ALTO-101 EEG"
X Link 2026-01-19T20:57Z [---] followers, [--] engagements
"$OGN : P/E [---] ( $2.4B) $CRMD : P/E [---] ( $592M) $ABEO : P/E [---] ( $287M) Not every biotech is trading at hype-level valuations. Some have massive valuation reset potential: $OGN: P/E [---] (mkt cap. $2.4B) $CRMD: P/E [---] (mkt cap. $592M) $ABEO: P/E [---] (mkt cap. $287M) Low multiples can often be found in small caps. Not every biotech is trading at hype-level valuations. Some have massive valuation reset potential: $OGN: P/E [---] (mkt cap. $2.4B) $CRMD: P/E [---] (mkt cap. $592M) $ABEO: P/E [---] (mkt cap. $287M) Low multiples can often be found in small caps"
X Link 2026-01-23T14:18Z [---] followers, [---] engagements
"$UTHR 🧬 UnitedTherapeutics MiroliverELAP Phase1 - ✅ 100% ✅ ➡ Phase2 : https://ir.unither.com//media/Files/U/United-Therapeutics-IR/documents/press-releases/2026/press-release-miroliverelap-phase-1-results.pdf 🧬 United Therapeutics ( $UTHR) hls spch v [--]. fzi studie miroliverELAP prvnch bioinenrsky vytvoench jater na svt. ✅ 100% peit u testovanch pacient ✅ dn vn vedlej inky ➡Smr [--]. fze Zdroj: https://t.co/BHfPmAHYSy https://ir.unither.com//media/Files/U/United-Therapeutics-IR/documents/press-releases/2026/press-release-miroliverelap-phase-1-results.pdf 🧬 United Therapeutics ( $UTHR) hls spch"
X Link 2026-01-27T10:33Z [---] followers, [--] engagements
"$RHHBY GLP-1/GIP CT-388 Phase2 $LLY $NVO $VKTX $RHHBY Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity. $LLY $NVO $VKTX https://t.co/k6KIIIUF8I $RHHBY Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity. $LLY $NVO $VKTX https://t.co/k6KIIIUF8I"
X Link 2026-01-27T10:57Z [---] followers, [---] engagements
"$ASPI $QLE $SKBL $QLE IPO HALEU ( ) $ASPI $QLE $SKBL Graphic we recently put together to help better understand how these companies connect. $QLE will be interesting to see how IPO and HALEU deadlines pan out. TerraPower made it clear $ASPI was the only company who could meet their timeline and demand. https://t.co/suZSl9Ok1p $ASPI $QLE $SKBL Graphic we recently put together to help better understand how these companies connect. $QLE will be interesting to see how IPO and HALEU deadlines pan out. TerraPower made it clear $ASPI was the only company who could meet their timeline and demand."
X Link 2026-01-30T13:53Z [---] followers, [---] engagements
"$GUTS Fractyl Health Revita FDA PMA DeNovo [--] FDA [-----] ( ) $GUTS Fractyl Health shares sank to a 52week low as it may shift Revitas FDA path from PMA to De Novo; FDA feedback due Q2 [----]. In REMAIN1 Revita cut postGLP1 weight regain (4.5% vs 7.5% at [--] months) with good safety; 12month data Q3 [----]. $GUTS Fractyl Health shares sank to a 52week low as it may shift Revitas FDA path from PMA to De Novo; FDA feedback due Q2 [----]. In REMAIN1 Revita cut postGLP1 weight regain (4.5% vs 7.5% at [--] months) with good safety; 12month data Q3 2026"
X Link 2026-01-30T17:02Z [---] followers, [---] engagements
"$CAPR FDA HOPE-3 Deramiocel BLA 🧬 DMD 📈 $CAPR just provided a major regulatory update on the Deramiocel BLA following FDA review of HOPE-3 data. 🧬 The market is laser-focused on the DMD approval timeline. Is the path to commercialization fully de-risked or are we facing a "delay-trap" 📈 $CAPR just provided a major regulatory update on the Deramiocel BLA following FDA review of HOPE-3 data. 🧬 The market is laser-focused on the DMD approval timeline. Is the path to commercialization fully de-risked or are we facing a "delay-trap" 📈"
X Link 2026-02-02T18:45Z [---] followers, [---] engagements
"$TLPH CRRT [--] 🧵 $TLPH Nafamostat cant compete with heparin because heparin is cheap and established imo. That leaves the other [--] % of CRRT market competing against citrate and no anticoagulation. 🧵 $TLPH Nafamostat cant compete with heparin because heparin is cheap and established imo. That leaves the other [--] % of CRRT market competing against citrate and no anticoagulation. 🧵"
X Link 2026-02-03T22:16Z [---] followers, [--] engagements
"$TLPH CRRT Citrate is expensive complex and is barely used in US. Docs rather not anticoagulate at all and pay for extra CRRT filters that clot more frequently due to no anticoagulation. Citrate is expensive complex and is barely used in US. Docs rather not anticoagulate at all and pay for extra CRRT filters that clot more frequently due to no anticoagulation"
X Link 2026-02-03T22:18Z [---] followers, [--] engagements
"$TLPH CRRT ( ) So real competition for nafamostat is no anticoagulation. Commercial incentive to anticoagulate is prolonging CRRT filter life. Nafamostat will likely double filter life so hospitals will need half as many filters if they use nafamostat. One filter is $500. So real competition for nafamostat is no anticoagulation. Commercial incentive to anticoagulate is prolonging CRRT filter life. Nafamostat will likely double filter life so hospitals will need half as many filters if they use nafamostat. One filter is $500"
X Link 2026-02-03T22:21Z [---] followers, [--] engagements
"$TLPH ( ) [---] So real competition for nafamostat is no anticoagulation. Commercial incentive to anticoagulate is prolonging CRRT filter life. Nafamostat will likely double filter life so hospitals will need half as many filters if they use nafamostat. One filter is $500. So real competition for nafamostat is no anticoagulation. Commercial incentive to anticoagulate is prolonging CRRT filter life. Nafamostat will likely double filter life so hospitals will need half as many filters if they use nafamostat. One filter is $500"
X Link 2026-02-03T22:22Z [---] followers, [--] engagements
"$TLPH [---] [---------] ( ) [--] million filters used in US per year. By using nafamostat vs no anticoagulation hospitals would need 300-400 thousand filters less so $175 million in cost savings per year. So $tlph peak sales estimate $200 mil seems realistic depending on final numbers of filter life. [--] million filters used in US per year. By using nafamostat vs no anticoagulation hospitals would need 300-400 thousand filters less so $175 million in cost savings per year. So $tlph peak sales estimate $200 mil seems realistic depending on final numbers of filter life"
X Link 2026-02-03T22:24Z [---] followers, [---] engagements
"$TLPH ( ) $TLPH [--] [--] million filters used in US per year. By using nafamostat vs no anticoagulation hospitals would need 300-400 thousand filters less so $175 million in cost savings per year. So $tlph peak sales estimate $200 mil seems realistic depending on final numbers of filter life. [--] million filters used in US per year. By using nafamostat vs no anticoagulation hospitals would need 300-400 thousand filters less so $175 million in cost savings per year. So $tlph peak sales estimate $200 mil seems realistic depending on final numbers of filter life"
X Link 2026-02-03T22:25Z [---] followers, [---] engagements
"@cluelessbio $TLPH"
X Link 2026-02-03T22:28Z [---] followers, [--] engagements
"$TLPH $CRMD [--] $TLPH $CRMD ( ) https://x.com/BussinBiotech/status/1899912549551783956 Back in March I highlighted the connection between $TLPH and $CRMD well before the private placements and strategic investments were announced publicly later in the year. https://t.co/KGp8z7HhgZ I fully expect my thesis to continue to play out culminating in a full https://x.com/BussinBiotech/status/1899912549551783956 Back in March I highlighted the connection between $TLPH and $CRMD well before the private placements and strategic investments were announced publicly later in the year."
X Link 2026-02-03T22:52Z [---] followers, [---] engagements
"$TLPH $CRMD [----] $CRMD $TLPH [----] Back in March I highlighted the connection between $TLPH and $CRMD well before the private placements and strategic investments were announced publicly later in the year. https://t.co/KGp8z7HhgZ I fully expect my thesis to continue to play out culminating in a full Back in March I highlighted the connection between $TLPH and $CRMD well before the private placements and strategic investments were announced publicly later in the year. https://t.co/KGp8z7HhgZ I fully expect my thesis to continue to play out culminating in a full"
X Link 2026-02-03T22:53Z [---] followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing